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Stem cell-based therapies are an important developing technology for treating 
cardiovascular ischemic disease, including subsequent co-morbidities such as ulcerative 
wounds. Mesenchymal stem cells (MSCs) have a proven ability to augment wound 
healing and neovascularization processes and have been more recently investigated for 
their endothelial-like behavior. This doctoral work aims to understand mechanisms 
underlying matrix-driven MSC tubulogenesis within PEGylated fibrin gels, specifically 
(1) why this behavior occurs and (2) if this behavior has clinical utility. 
Briefly, a three-dimensional morphological quantification pipeline was first 
developed for analyzing the maturity of vascular networks (Chapter 2). This method was 
applied in later studies that examined the full spectrum of MSC behavior in PEGylated 
fibrin gels, linking biomaterial properties with network development (Chapter 3). 
Mechanisms underlying the cell-matrix relationship were more fully clarified through 
gain-of-function cell studies. These studies indicated that PEGylated fibrin promotes 
endothelial-like MSC behavior through a combination of hypoxic stress and bioactive 
fibrin cues (Chapter 4). Notably, this endothelial-like MSC behavior closely mirrored 
vasculogenic mimicry, a process whereby tumors establish non-endothelialized 
vasculature in response to hypoxic stress. The functionality of these tumor vessels 
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suggests that mature endothelial differentiation of MSCs may not be necessary to achieve 
therapeutically beneficial tissue perfusion. This hypothesis opens up new mechanisms for 
exploitation in vascular tissue engineering strategies. 
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Chapter 1: Introduction 
BACKGROUND AND MOTIVATION 
Ischemic disease and cell-based revascularization 
Ischemic cardiovascular diseases continue to be the leading source of death and 
disability in the Western World and a tremendous fiscal burden on the healthcare 
system.1,2 Coronary heart disease (CHD) and peripheral arterial disease (PAD) are 
particularly widespread.1,3,4 Patients with these conditions are at a heightened risk for 
further complications, including myocardial infarction, critical limb ischemia, and 
chronic wounds, which require increasingly costly medical intervention.5,6 Since ischemic 
cardiovascular diseases are frequently symptomatic of a more systemic co-morbidity 
(e.g., metabolic syndrome, diabetes, or obesity), many of these patients have 
compromised healing abilities and make poor surgical candidates.5 This trend leads to an 
increasing population of “no-option” patients who are either ineligible for current 
interventions or for whom interventions fail to alleviate disabling ischemia.2 New 
strategies are needed to treat these “no-option” patients as well as improve long-term 
outcomes for the general populace, thereby reducing the rate of future revisional 
procedures and overall healthcare costs. 
Regenerative medicine and tissue engineering are at the forefront of next-
generation therapies to revascularize ischemic tissues. After suboptimal trials with 
angiogenic protein and gene delivery,4,7 stem cell-based therapies rapidly gained 
popularity among medical and research communities. Specifically, bone marrow-derived 
and adipose-derived mesenchymal stem cells (MSCs) have emerged as viable candidate 
populations: these progenitors are easy to harvest through a simple biopsy, can be readily 
expanded ex vivo, and potentiate angiogenesis and tissue repair.8-12 Autologous stem cell 
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transplants have yielded promising results in laboratory and early clinical studies. In post-
myocardial infarction patients, an infusion of bone marrow MSCs led to a sustained 18% 
increase in left ventricular ejection fractions.13 Similarly, intramuscular injection of MSC 
significantly reduced limb ischemia associated with PAD by increasing local 
angiogenesis. They found that MSC-generated neovascular networks provided an 
auxiliary blood flow to restore limb perfusion and reduce ischemia-associated limb pain.5 
In another clinical trial, MSCs topically delivered within a fibrin spray facilitated the 
closure of severely chronic wounds.14 Results showed that the probability of wound 
closure correlated strongly with the number of MSCs delivered and that MSC-treated 
wounds had diminished scarring and improved tensile strength. These early trials 
showcased the feasibility of MSC therapies becoming a reality as well as the adaptability 
of application and flexibility of delivery these cells offer. 
 
Challenges facing stem cell-based ischemic therapies 
Despite the successes of early trials, MSC therapies have also experienced a 
number of setbacks. Diabetic patients, for example, suffer from hyperinsulinemia-
induced oxidative stress that limits the regenerative and angiogenic potential of their stem 
cells.15 In a type-II diabetes mouse model, MSCs favored adipocytic over endothelial 
differentiation and resulted in significantly fewer animals with resolved limb ischemia.15 
Other diseased states may be similarly contraindicative for stem cell-based therapies.16 
These patients would require an additional therapeutic step during ex vivo expansion that 
restores normal MSC function prior to transplantation. 
On top of intrinsic patient health issues, MSC retention at the transplantation site 
has been and remains universally poor. In vivo studies have reported transplanted cell 
 3 
death up to 70-100%.17 A considerable percentage of dead cells are located in construct 
cores, which are diffusionally limited and prone to hypoxia-induced apoptosis. This 
phenomenon is a known challenge in engineering thick tissue constructs. However, cells 
located along the periphery of constructs surprisingly fail to thrive as well. Studies 
verified that MSCs are not migrating away from the implant site nor are they 
experiencing extreme hypoxia like the cells in the construct core.17 Instead, evidence 
suggests an alternative (but unknown) mechanism is triggering the cascade of peripheral 
cell death. Attempts to salvage MSC retention have focused on activating survival 
mechanisms by heat or hypoxic stress preconditioning, specifically heat shock protein 
(HSP) and hypoxia inducible factor (HIF) pathways.18-21 Although the nomenclature 
suggests that these pathways are two distinct survival mechanisms, studies have 
demonstrated a great deal of molecular overlap between HSP- and HIF-mediated cell 
behavior.22,23 Both families of survival proteins have also been the focus of MSC gene 
therapies that mimic the beneficial effects of preconditioning without the physical 
presence of stress.24 HIF pathways, though, have been specifically linked to an 
upregulation of angiogenic MSC behavior.21,25 In gene activation studies, constitutive 
expression and stabilization of HIF-1α in MSCs enhanced paracrine production of 
angiogenic factors.26 Given hypoxia’s innate role in cuing wound revascularization, the 
relationship between hypoxic stress and angiogenic stem cell behavior follows as a 
natural extension of that paradigm. 
 
MSC-to-endothelial differentiation: fact or false-positive? 
The biggest setback to implementing MSC therapies—and perhaps the most 
controversial—is the ability (or inability) of these populations to fully differentiate into 
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endothelial cells.27 While paracrine mechanisms are well characterized as the primary 
mode of MSC contribution to the ischemic wound environment,28 this cell behavior 
undermines the central principle of tissue engineering: the physical replacement of dead 
or damaged tissue with a transplanted cell population.29 This principle is especially 
crucial for patients with co-morbidities that limit their healing capacity; in such cases, 
paracrine signaling may not be enough to promote neovascularization.30 The transplanted 
cells need to physically transition into the new desired tissue. In this case, the MSCs need 
to be directed into endothelialized vasculature. 
As a mesenchyme or stromal progenitor, MSCs are generally defined by their 
ability to differentiate into adipocytes, chondrocytes, and osteoblasts.8 Their ability to 
differentiate into other mesodermal lineages, such as myoblasts, has also been 
reported.31,32 In the last ten years, MSCs have more recently been investigated for their 
endothelial potential as a new cell source for neovascularization.33 Mature endothelial 
cells are characterized by a number of key phenotypic markers: von Willebrand Factor 
(vWF), vascular endothelial cadherin (VE-cadherin), platelet endothelial cell adhesion 
molecular (PECAM)-1, vascular endothelial growth receptor (VEGFR)-1 (i.e., Flt-1) and 
VEGFR-2 (i.e., KDR/Flk-1), CD34, and Tie-2.34,35 Studies reporting successful 
differentiation of MSCs towards a putative endothelial cell type frequently cite positive 
gene and protein expression for a combination of these endothelial markers (Table 1.1). 
However, our group and others have experienced inconsistent reproducibility of these 
results. This inconsistency has raised questions regarding the purity of initial MSC 
cultures and the possibility of contaminating progenitors or rare endothelial cells leading 
to false-positive results.27 
The purity and differentiation potential of MSC populations depends significantly 
on the tissue source and isolation method.8,27,36 From bone marrow, MSCs are typically 
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harvested as the adherent cell fraction,37 which is now known to be less homogenous than 
previously thought. Cell sorting for surface markers (CD29, CD90, CD105, CD73, 
CD44, and Stro-1)38 can enrich the adherent fraction for MSCs but a margin of error up to 
5-10% may remain. Additional sources of ambiguity arise in identifying contaminating 
cell populations. New studies indicate that endothelial cells can transdifferentiate towards 
a multipotent stromal lineage, adopting a spindle-like morphology and expressing surface 
markers CD90, CD44, and Stro-1 characteristic of MSCs.39 Others have observed hybrid 
mesenchymal-endothelial phenotypes where subpopulations of progenitors 
simultaneously express MSC and endothelial surface markers.36 Both scenarios highlight 
the present difficulty in distinguishing between true MSC-to-endothelial differentiation 
and false-positive results obtained from incidental subpopulations. Clear methods to 
untangle these overlapping cell populations are currently lacking.40 The difficulty in 
verifying MSC purity confounds the results obtained from these populations and is a 
likely source of inter-study variability. 
Our group’s work is predicated on driving MSCs towards an endothelial-like 
phenotype to facilitate local revascularization. Throughout this endeavor, we have 
encountered phenotypic inconsistency with one endothelial marker in particular: 
PECAM-1.41 PECAM-1 is highly specific to mature endothelium and is only second in 
specificity to Tie-2, since macrophages are also capable of PECAM-1 expression.42,43 
While our MSCs have consistently expressed vWF and VE-cadherin, the lack of 
PECAM-1 protein in recent studies has caused us to question the endothelial nature of 
our cell outcomes. The work presented here seeks to understand that very issue—is 
endothelial differentiation truly what MSCs are accomplishing and if not, do they still 
have therapeutic utility in cell-based ischemic therapies? 
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Matrix-directed MSC behavior for ischemic therapies 
Biomaterials are often employed to enhance stem cell-based therapies. These 
engineered matrices can act as a delivery vehicle for improved cell retention and can 
coordinate and direct stem cell behavior to achieve specific outcomes.44 For large dermal 
wounds, biomaterials also serve as a spatial filler to reduce the rate of purse-strong 
closure and minimize scar tissue formation.11,45-47 The use of biomaterials to direct stem 
cell behavior through mechanotransduction and biochemical signaling has been well 
documented.48,49 A landmark study by Engler et al importantly demonstrated that matrix 
stiffness alone could direct MSCs towards different lineages.50 Synthetic polymers excel 
in facilitating highly tunable systems with specific biomechanical qualities and 
degradation profiles.51 Similarly, the biomaterial itself is often a source of intrinsic 
biochemical cues, engineered to mimic the microenvironment of the target tissue. Natural 
polymers are inherently bioactive and elicit cellular responses based on normal 
physiologic programming; their bioactivity is highly advantageous over synthetic 
polymers where complex chemistries are usually required to decorate the matrix with 
growth factors and cell-binding peptides.51  
PEGylated fibrin is a natural-synthetic polymer blend that merges the benefits of 
both polymer families. Fibrin, derived from thrombin’s cleavage of fibrinogen, is a 
protein from the clotting cascade and initiates the natural wound-healing response and 
angiogenic cell behavior.52 However, the body’s natural anti-thrombotic mechanisms 
include fibrinolytic enzymes that lead to rapid degradation of naked fibrin in vivo.53,54 
Polyethylene glycol (PEG), on the other hand, is a biologically inert polymer frequently 
used in hydrogel applications and as a “stealth” coating that minimizes the 
immunogenicity of delivered biologics.55 The merged PEGylated fibrin product 
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subsequently combines the bioactivity of fibrin with slowed enzymatic breakdown of the 
matrix imparted by PEG’s “stealth” protection.56-58 
The novelty of our work lies in how PEGylated fibrin directs MSC behavior. 
PEGylated fibrin is able to promote spontaneous MSC tubulogenesis without the addition 
of soluble factors in the culture media.41 Tube network formation is complemented by the 
upregulation of several endothelial-like markers (vWF and VE-cadherin) and angiogenic 
paracrine factors (e.g., VEGF). Though biomaterials can provide significant cell-fate 
direction, growth factors are still frequently added to supplement these cues during the 
differentiation process.50 Growth factors add expense and complexity, which are both 
barriers to clinical translatability. We believe that simplicity is key to successful 
translation of cell-based ischemic therapies to the clinic and PEGylated fibrin enables us 
to use one biomaterial and one cell source. 
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SPECIFIC AIMS 
The doctoral work here aims to clarify how fibrin PEGylation contributes to the 
matrix dynamics facilitating MSC tubulogenesis and which cell mechanisms are active 
during this process. Elucidating mechanisms of MSC tubulogenesis will lay the 
groundwork for future re-engineering of our biomaterial matrix to achieve in vivo 
postnatal vasculogenesis of this progenitor population. By fully utilizing the regenerative 
capacity of progenitor populations, we can increase the clinical efficacy of cell-based 
vascular therapies. 
 
Aim 1: Develop a morphological quantification method for analyzing vascular 
network development. 
Rationale: Validating vascular tissue engineering strategies requires analysis of 
morphological outcomes. Current methods rely on two-dimensional techniques 
that eliminate valuable spatial information. A three-dimensional technique will 
provide more accurate analysis for future investigation of MSC tubulogenesis. 
A. Optimize staining protocol for fluorescent microscopy of whole gel constructs. 
B. Synthesize an image quantification pipeline for extracting three-dimensional 
data from microscopy images and outputting vascular-relevant metrics. 
C. Validate new method using previous morphometry protocols and assays, 
including two-dimensional network tracing and aortic ring outgrowth. 
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Aim 2: Determine the impact of fibrin PEGylation on the morphologic and 
phenotypic changes of MSCs.  
Rationale: Fibrin matrices are a common natural polymer in vascular tissue 
engineering but these networks are unable to induce tubulogenesis without 
additional soluble factors. Outcomes aim to characterize cell changes associated 
with biomaterial properties of PEGylated fibrin. 
A. Characterize rheological and diffusional properties of fibrin-based gels. 
B. Assess MSC tubular networks by quantitative morphometry (from Aim 1) and 
verify lumenal space development. 
C. Determine cytoskeletal and integrin components responsible for cell motility 
D. Measure biologic response of MSCs via cell proliferation, protein marker 
expression, and secreted factor production. 
E. Implicate potential mechanisms that link results from 2A and 2B. 
 
Aim 3: Investigate the mechanisms responsible for endothelial-like MSC behavior in 
PEGylated fibrin gels. 
Rationale: MSCs in PEGylated fibrin exhibit a partial endothelial phenotype. The 
utility of endothelial-like cell behavior and why PEGylated fibrin elicits this cell 
response remains unknown. Understanding both questions is central to directing 
future applications of our cell-based ischemic therapy. 
A. Compare phenotypic and morphologic outcomes of MSCs to endothelial cells. 
B. From results of 2E, explore how implicated mechanisms modulate endothelial-
like behavior of MSCs. 
C. Validate findings of 3B with an in vivo model. 
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Study MSC source 
Method of 
differentiation Phenotypic outcomes 
Yan 201315 mBM  Nox4 siRNA  
↑CD31+ 
↓adipocytic diff. 
Wang 201359  rBM hBM 
VEGF (rBM) 
VEGF + bFGF (hBM) 
 
MRTF-A siRNA 
↑Flt-1, Flk-1, vWF, VE-cadherin 
 
 
↓Flt-1, Flk-1 
Galas 201360 hBM EGM-2 (-VEGF) 
vWF+/Flk-1+/VE-cadherin+ 
1 week: ↑CD31 
2 week: ↑vWF, DiI-ac-LDL uptake 
Wang 201361 hTB hBM 
Matrigel + M200 EGM 
for 4h 
 
FOXC2 siRNA 
hTB: ↑CD31, Flk-1, CD144, vWF 
hBM: (no expression observed) 
 
hTB: ↓CD31, CD144 
Huang 201362 mBM miR-126 miRNA + VEGF + bFGF 
↑PI3K p85, Akt, p38, ERK1 
↑CD31, E-selectin, vWF, Flk-1 
↓CD29, CD90, CD105 
DiI-ac-LDL uptake 
day 9: cobblestone morphology 
Janeczek 201263 hBM EGM-2 + shear flow for 10d + Matrigel 
↑CD31, Flk-1, vWF 
DiI-ac-LDL uptake 
Benavides 
201264 hAF EGM + added VEGF 
↑vWF, eNOS, CD31, VE-cadherin, Flk-1 
↓c-kit, SSEA4 
DiI-ac-LDL uptake 
Pankajakshan 
201265 pBM EGM + added VEGF 
↑vWF, VE-cadherin, CD31, Flt-1, Flk-1 
DiI-ac-LDL uptake 
 
Wingate 201249 rBM modulating stiffness of nanofiber grafts 
3kPa graft: ↑Flk-1, ↓SMA 
>8kPa grafts: ↓Flk-1, ↑SMA 
Zhang 201041 hBM PEGylated porcine fibrin matrices CD31+/vWF+/VE-cadherin+/Flk-1+ 
Xu 200966 rBM 
simvastatin 
 
 
Notch1 siRNA, DAPT 
↑vWF, CD31, VE-cadherin, Flk-1 
↑Notch1, Notch4, DLL4 
 
↓vWF, VE-cadherin, Flk-1 
Hamou 200967  mAT hypoxia + VEGF 
↑Flk-1+/CD31+  
DiI-ac-LDL uptake 
Jazayeri 200868 hBM VEGF + IGF-1 
↑vWF, CD31, Flt-1, Flk-1, Tie-2, VCAM-1 
formation of Weibel Palade bodies, caveolae, 
and pinocytic vesicle  
Oswald 200433 hBM VEGF ↑KDR, Flt-1, vWF, VCAM-1, VE-cadherin 
Table 1.1: Summary of recent studies analyzing MSC transdifferentiation towards an 
endothelial lineage. Abbreviations: bone marrow (BM), adipose tissue (AT), 
trabecular bone (TB), amniotic fluid (AF), endothelial growth media 
(EGM). Species of MSC source is denoted by human (h), rat (r), mouse (m), 
pig (p). 
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Chapter 2: 3D Image Quantification as a New Morphometry Method 
for Evaluating Vascular Network Development 
OVERVIEW AND AIMS 
Chapter 2 focuses on the development of a three-dimensional morphological 
quantification method as described in Aim 1, which is applied in Chapters 3 and 4 to 
validate MSC network development.*  
 
Aim 1: Develop a morphological quantification method for analyzing vascular 
network development. 
Rationale: Validating vascular tissue engineering strategies requires analysis of 
morphological outcomes. Current methods rely on two-dimensional techniques 
that eliminate valuable spatial information. A three-dimensional technique will 
provide more accurate analysis for future investigation of MSC tubulogenesis. 
A. Optimize staining protocol for fluorescent microscopy of whole gel constructs. 
B. Synthesize an image quantification pipeline for extracting three-dimensional 
data from microscopy images and outputting vascular-relevant metrics. 
C. Validate new method using previous morphometry protocols and assays, 
including two-dimensional network tracing and aortic ring outgrowth. 
 
 
 
                              
        
*Significant portions of this chapter have been published in Rytlewski JA, Geuss LR, Anyaeji CI, Lewis 
EW, Suggs LJ. Three-dimensional image quantification as a new morphometry method for tissue 
engineering. Tissue Engineering Part C: Methods. 2012 July;18(7):507–516. Portions have been used with 
copyright permission from Mary Ann Liebert, Inc. 
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INTRODUCTION 
Since the concept of tissue engineering was first introduced, in vitro cell culture 
has progressed from two-dimensional (2D) monolayers to three-dimensional (3D) 
extracellular matrix (ECM)-mimicking materials.1 Now, encapsulating cells in 3D 
matrices is a common approach towards recapitulating the physiological niches of the 
human body. While numerous 3D substrates are available for in vitro tissue engineering 
models and applications, most methods of validation and quantification are still limited to 
2D space (e.g., histological sectioning or single-plane microscopy). For engineered 
tissues, determining the success or failure of an approach relies heavily on morphological 
characterization to ascertain whether or not the desired cell types have been achieved. 
Morphometry can be further confounded in tissues originating from stem cell or 
progenitor lines where cell morphologies have the potential for even greater variation. 
Thus, an objective quantification pipeline is ideal, if not essential, to generate 
morphologic results with reliable significance and clear biological relevance. 
 
Over the last decade, computational methods have facilitated the transition from 
observer-based histology to more quantitative measures.2,3 Researchers can now choose 
from powerful commercial suites (e.g., Imaris, Lucis, Metamorph) capable of 3D and 4D 
image analysis and data processing.4,5 Unfortunately, commercial software is often cost-
prohibitive; hence, many computational techniques utilize and modify open-source 
packages such as NIH’s ImageJ (Bethesda, MD). For example, microscope images can be 
manually traced by the user to quantify branch-like cellular morphologies.6,7 More semi-
automated methods rely on image segmentation to quickly derive surface area, perimeter 
length, and lacunarity measurements of tissue structures or cell growths.8-13 However, 
these methods are based on 2D image analysis, which approximates 3D cellular 
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architecture with 2D planar projections. This approach is even less accurate when tissues 
exhibit anisometric growth patterns that fall outside the plane of imaging. 
 
A number of challenges exist in morphological quantification of engineered 
microvasculature. This subset of cardiovascular tissue engineering aims to repair 
ischemic tissues by enhancing the natural processes of angiogenesis and vasculogenesis.14 
On the gross morphological scale, native microvasculature exhibits an arborealized 
hierarchical organization; however, on the microscale, these tubular structures have 
highly irregular geometries, making morphological analysis a complex and difficult 
process.15 Prior to computational methods, histological sections were either subjectively 
scored according to the degree of network extensiveness (e.g., graded 1-5) or vessel 
numbers could be manually determined with Chalkley counts.16,17 Since the advent of 
computational methods, studies report 2D metrics like vascular outgrowth lengths, 
network surface area-to-perimeter ratios, and microvascular densities (MVD).16,18 While 
such techniques provide relative measures for comparison, the indirectness of 2D 
quantification creates two fundamental flaws: these morphological metrics fail to capture 
all possible spatial information and can lead to misleading conclusions when taken out of 
context. Varying degrees of observer (or user)-based subjectivity may further diminish 
the data’s credibility. Hence a need exists to improve the current approach of 
morphological quantification in vascular tissue engineering and in tissue engineering as a 
whole. 
 
To overcome some of the pitfalls of 2D methods, we assembled a quantitative 
pipeline for 3D morphological analysis based on 3D Slicer (www.slicer.org), an open-
source MRI/CT software package.19-21 We chose an open-source package as the backbone 
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for this method to encourage method adoption and collaboration. Specifically, this 
pipeline consists of three distinct protocols: (1) fluorescent staining of cells concomitant 
with confocal imaging; (2) enhancement and segmentation of confocal images with 3D 
model generation in 3D Slicer’s Vascular Modeling Toolkit (VMTK, www.vmtk.org)22,23; 
and (3) computational analysis of 3D data into quantitative metrics using MATLAB® 
(MathWorks, Natick, MA). In the work presented here, we used two well-established 
angiogenesis assays as bases for demonstrating the validity and utility of 3D 
morphological quantification. The Nehls-Drenckhahn microcarrier bead assay24 was used 
to demonstrate progenitor-derived tubulogenesis within variations of our previously 
reported PEGylated fibrin gels. PEGylated fibrin is uniquely able to direct progenitor 
cells towards an endothelial phenotype without the addition of soluble factors.25-27 Briefly, 
this assay encapsulated bone marrow-derived human mesenchymal stem cells (MSCs) 
seeded on collagen-coated microcarrier beads (MCBs) in fibrin-based gels. The MCBs 
served a dual purpose, to support tubulogenic sprouting and to provide an artificial origin 
for quantitative analysis. The rat aortic ring assay served as an alternative in vitro model 
to better understand implications of the MCB studies.28,29 With these experiments, we aim 
to show that a) our quantification pipeline allows us to successfully generate tailored 3D 
metrics for engineered vascular networks and that b) 3D metrics are significantly more 
accurate and insightful than their 2D analogues. 
 
MATERIALS AND METHODS 
Experimental Design 
To illustrate the utility of this 3D quantification method, we explored two 
variables of fibrin-based gel composition: PEGylation and fibrin concentration. In 
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PEGylated fibrin gels, the molar ratio of fibrin-to-PEG remained constant across fibrin 
concentrations. From these two variables, we devised three experimental groups: 
10mg/mL fibrin + 1mg/mL PEG, 7.5mg/mL fibrin + 0.75mg/mL PEG, and 5mg/mL 
fibrin + 0.5mg/mL PEG. Each fibrin concentration had a corresponding fibrin (only) 
control: 10mg/mL fibrin, 7.5mg/mL fibrin, and 5mg/mL fibrin. Matrigel, as a well-
characterized commercial material for angiogenesis, served as a reference-type control.30 
 
Materials 
Dulbecco’s phosphate buffered saline (PBS), phenol red-free low-glucose 
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), 
GlutaMAXTM-I (100x), and Calcein AM were obtained from Invitrogen (Carlsbad, CA). 
Endothelial growth media-2 (EGM-2) was purchased as a bullet kit from Lonza (Basel, 
Switzerland). Fibrinogen from human plasma (50-70% protein, ≥80% clottable), 
thrombin from human plasma (≥1,000NIH units/mg protein), collagen-coated Sigma-
Solohill microcarrier beads, and 37% formaldehyde were obtained from Sigma-Aldrich 
(St. Louis, MO). Penicillin-streptomycin and trypsin/EDTA were obtained from ATCC 
(Manassas, VA). Phenol red-free growth factor-reduced Matrigel was obtained from BD 
Biosciences (San Jose, CA). Homo-difunctional succinimidylglutarate polyethylene 
glycol (PEG-(GS)2, 3400 Da) was obtained from NOF America (White Plains, NY). 
 
Cell maintenance 
Bone marrow-derived MSCs (Lonza, Basel, Switzerland) were cultured and 
expanded in tissue culture-treated plastic flasks (Corning, Corning, NY) with DMEM 
containing 10% FBS, 1% penicillin-streptomycin, and 2nM GlutaMAXTM-I. As stated by 
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the manufacturer, MSCs were derived from normal bone marrow culture; this 
subpopulation tests positive for CD105, CD166, CD29, and CD44 and tests negative for 
CD14, CD34 and CD45. All cell cultures were incubated at 37°C with 5% CO2. 
 
Cell seeding of microcarrier beads 
Collagen-coated microcarrier beads (MCBs) were autoclaved in PBS according to 
the manufacturer’s instructions. MCBs were primed in serum-supplemented DMEM for 1 
hour at 37°C. MSCs (passage 3-5) were then trypsinized, centrifuged into a pellet, and re-
suspended with collagen-coated microcarrier beads (MCBs) at a concentration of 1.4x106 
cells/20mg MCBs. The culture was gently agitated every 30 minutes over a 4-hour 
incubation period to minimize MCB aggregation. After seeding, the MCB culture was 
passed through a 70µm cell strainer and rinsed with PBS to remove unattached cells. The 
MCB culture was finally resuspended in media at a concentration of 20mg MCBs/mL. 
 
Preparation of gel components 
Human fibrinogen (Fgn) was prepared at concentrations of 80mg/mL, 60mg/mL, 
and 40mg/mL in PBS, pH 7.8, and solubilized for 2-3 hours in a 37°C water bath. PEG-
(GS)2 was solubilized immediately before use at 8mg/mL, 6mg/mL, and 4mg/mL in PBS, 
pH 7.8. Human thrombin was reconstituted in sterile ddH2O at 100U/mL per the 
manufacturer’s instructions and frozen at -80°C. Frozen thrombin aliquots were thawed 
and diluted to a final concentration of 25U/mL in 30mM CaCl2. All three solutions were 
sterile-filtered (0.22µm pore size). 
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PEGylation of fibrinogen and gelation 
Fgn was combined with an equal volume of PEG-(GS)2 (1:10 molar ratio) for 3 
minutes at room temperature to allow for PEGylation. In control gels, PBS was 
substituted for PEG-(GS)2. The MCB suspension was diluted 1:5 with media and 
combined with an equal volume of PEGylated Fgn (or PBS + Fgn) in two-chambered 
coverglass (Nuncbrand Lab-Tek II; Thermo Scientific, Rochester, NY). The solution was 
briefly mixed to evenly suspend MCBs. Gels were enzymatically crosslinked with an 
equal volume of thrombin, yielding a final concentration of 10mg/mL Fgn and 1mg/mL 
PEG-(GS)2. For the 1mL gels made here, exact volumes of each component were 125µL 
Fgn, 125µL PEG-(GS)2 (or PBS), 250µL of 1:5 diluted MCBs, and 500µL thrombin. 
Unreacted PEG-(GS)2 was removed by rinsing the gels with 3-4 volumes of media. 
Finally, serum-supplemented media was added to the gels and changed daily for 7 days. 
 
Rat aortic ring culture 
Rat aortas were a gift from the lab of Dr. Christine E Schmidt. Briefly, Fischer 
rats were given an intraperitoneal injection of 1000U/kg heparin 15min prior to perfusion 
with PBS. Proximal aortas were harvested and rinsed in PBS. Under a dissection scope, 
fibroadipose tissue was removed and aortas sliced into 1mm thick rings. Rings were 
rinsed three times in an anti-contamination cocktail (EMG-2 with Gentamicin) before a 
final rinse with EMG-2. 10mg/mL PEGylated fibrin gels were prepared as described 
above. To encapsulate aortic rings, 125µL of gel was first polymerized in each well of an 
eight-chambered coverglass (Nuncbrand Lab-Tek II). Aortic rings were vertically placed 
in the center of each well, and then another 125µL of gel was polymerized on top. As 
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before, gels were rinsed to remove unreacted PEG-(GS)2. Aortic rings were cultured for 7 
days with EGM-2. 
 
Fluorescent staining 
On Day 7, gels were rinsed with fresh PBS (with Ca+2, Mg+2) every 15 minutes for 
a total of 90 minutes. PBS was removed and 10µM Calcein AM was added for 1 hour. 
Gels were subsequently rinsed with PBS every 5 minutes for a total of 20 minutes, fixed 
with 4% neutral-buffered formalin for 30 minutes, and then rinsed again 2-3 times with 
PBS. 
 
Confocal microscopy 
A confocal scanning microscope (SP2 AOBS; Leica Microsystems, Bensheim 
Germany) was used to collect fluorescent image stacks. Under a 10x objective with 
512x512 image resolution, Calcein AM was excited with an Argon laser at 496nm and 
emission was detected from 510-520nm. The z-slice thickness was adjusted to maintain 
isometric voxel dimensions (approximately 3µm in each plane). Three z-stacks were 
collected per experimental group. For the MCB assay, each stack focused on one MCB 
and its cellular outgrowth. For the aortic ring assay, we limited each field of view to 
approximately 50% of the specimen due to size constraints. 
 
Image processing and 3D data generation 
All image processing was done in a 64-bit Linux (Ubuntu, Natty Narwhal 
distribution) environment with 8GB of memory. Each confocal stack (Figure 2.1A) was 
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first converted into a Visualization Toolkit (.vtk) file using the VTK Writer in ImageJ’s 
3D IO plug-in (Release 1.2.4; ImageJ Plugin Project). The resulting binary .vtk was 
loaded into 3D Slicer (Release 3.6, 64-bit Linux) as a volume and processed as follows 
(default values were used unless otherwise stated): 
 
1. An additive arithmetic filter was twice applied to quadruple original pixel 
values. This enhanced dimly fluorescent regions and improved the detectability of 
valuable pixels. 
 
2. Prepared image volumes were preprocessed in VMTK’s Vessel Enhancement 
module (downloaded June 2010), based on Frangi’s vesselness function. Settings 
were changed to a minimum diameter of 0.1, maximum diameter of 5.0, plate-like 
and line-like structure of 0.2, blob-like structure of 200, and a contrast threshold 
of 10. This algorithm predicts which image regions contain tubular structures via 
eigenvalue analysis of the local Hessian matrix at multiple length scales.31,32 
Therefore, continuous paths of fluorescence were intensified while background 
noise was suppressed (Figure 2.1B). 
 
3. Prior to segmentation, source seeds were manually placed at all network origins 
directly connected to the MCB and the threshold slider set to 0.05. Cell origins 
not directly attached to the MCB were ignored. These user-placed seeds 
initialized the Fast Marching Upwind Gradient (FMUG) used by VMTK’s Easy 
Level Set Segmentation module.23,33-35 By omitting target seeds at this step, the 
algorithm was allowed to determine terminal points for each network instead of 
the user. The 3D polydata model produced by FMUG (Figure 2.1C) was then 
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smoothed by Geodesic Active Contours evolution (Figure 2.1D and 2.1E). 
Evolution settings were changed to an inflation of 60, curvature of 60, and 
attraction to ridges of 40. Adequate model inflation was essential since the next 
step is extremely sensitive to surface noise. 
 
4. In VMTK’s Centerlines, target seeds were manually placed at all network ends 
as they appeared in the evolved 3D model (Figure 2.1F). Source and target 
fiducial lists were used by VMTK to calculate an imbedded Voronoi diagram 
(Figure 2.1G). Geometrically, the connected vertices of the Voronoi diagram 
correspond to the circumcenters of internal tetrahedra (based on Delaunay’s 
tessellation).23,33,35 Thus, these vertices represent a path equidistant to local 
surfaces at each plotted point, i.e., the model’s centerline. Centerlines data were 
extracted (Figure 2.1H) and exported to a text (.txt) file as xyz-coordinates with 
associated radii. 
 
Image data analysis and quantification 
A brief MATLAB (Release 2008a for Macintosh) program was coded to process 
the centerlines.txt file into descriptive metrics. Table 2.1 lists and defines key terms and 
metrics used to define this data; a corresponding schematic of these definitions is 
provided in Figure 2.2. Non-unique coordinates were removed before parsing the 
remaining coordinates into their respective discrete paths (i.e., microvascular network 
segments) such that no regions were retraced. A user-input threshold determined the start 
of a new segment such that a distance greater than the threshold indicated a 
nonconsecutive coordinate; in all cases, a value of 5-10 voxels was sufficient. Voxel 
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space was converted back to original physical dimensions (microns) using the scalar 
information recorded during image capture. Five metrics were directly calculated from 
this coordinate data: (1) segment volume36, (2) 3D segment length, (3) 2D xy-plane 
segment length, (4) 2D xz-plane segment length, and (5) 2D yz-plane segment length. 
Two additional metrics, (6) number of segments per network and (7) degree of branching 
per network were directly taken from the number of segments parsed and source/target 
fiducial lists, respectively. Segment metrics (1-5) were summed to obtain whole network 
metrics. 
 
Statistical analysis 
The assumption of normality was first confirmed with a Shapiro-Wilk w-test. A 
two-way analysis of variance was applied to each quantitative metric to determine 
significance between fibrin concentrations and PEGylation. Where significance was 
found, post-hoc tests were performed to further determine specific relationships of 
statistical significance. Bonferroni was applied where appropriate. Linear regression was 
used to determine the strength of correlation between types of length measurements (e.g., 
3D versus 2D xy-plane) with a supplementary ANOVA to ascertain whether the slope 
was zero. All statistical tests were completed in JMP (Release 9.0.2; SAS Institute Inc., 
Cary, NC). 
 
RESULTS AND DISCUSSION 
Samples were stained, fixed, and imaged on day 7 of culture. Representative 
confocal images with overlaid models are given for each MCB group in Figure 2.3. From 
these images, we observed that PEGylated fibrin encouraged more extensive vascular 
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networks than fibrin. MSCs in fibrin possessed a more proliferative and migratory 
phenotype instead, with more cells present but fewer incorporated into networks. 
Marginal, if any, differences were evident between the fibrin concentrations examined 
within both the PEGylated fibrin and fibrin groups. These qualitative observations 
collectively suggest that fibrin PEGylation is the greater contributing factor in MSC 
tubulogenesis than fibrin concentration within our in vitro system.  
 
Validity of 3D Slicer and computational artifacts 
We noticed a consistent computational artifact during the generation of 3D 
models: in networks with extensive branching (primarily the PEGylated fibrin groups), 
some branches appeared to be prematurely cropped before their natural termini. We 
suspect inhomogeneous intracellular dye distribution created regions of weak fluorescent 
signal that the marching front segmentation algorithm was unable to bridge. To verify 
that this computational error did not adversely affect our results, we benchmarked our 
method against an existing 2D approach based on manual tracing of network outgrowths 
(ImageJ Simple Neurite Tracer). Lengths from each method were appropriately matched 
in the 2D xy-plane. Figure 2.4 shows 2D network lengths generated in 3D Slicer 
alongside those generated in ImageJ for 10mg/mL PEGylated fibrin and its 
corresponding (unmodified) fibrin control group. Network lengths calculated from 3D 
Slicer and ImageJ were not statistically different, indicating that the computational 
artifact did not skew the value of our calculations. Similarly, both methods were able to 
demonstrate that PEGylated fibrin networks were significantly longer than fibrin 
controls. This study led us to conclude that our method is reasonably calibrated to 
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previously reported techniques, producing similar values and maintaining statistical 
discrimination power. 
 
Comparison of 2D versus 3D morphological quantification of vascular networks 
Four different measures of vascular network length were calculated for all seven 
experimental groups (Figure 2.5): 3D length, 2D length in the xy-plane, 2D length in the 
xz-plane, and 2D length in the yz-plane. All measures were derived from 3D Slicer data. 
When comparing the four different length measures within each experimental group, we 
found that 2D lengths repeatably failed to agree with their 3D counterpart. This trend 
appears to directly correlate with the extent of network outgrowth, with PEGylated fibrin 
groups having the greatest variability. Despite overall inconsistencies, linear regression 
models indicated strong similarities between 2D xy-plane and 3D network lengths (R2 > 
0.99). ANOVA confirmed this correlation for the 7.5mg/mL and 5mg/mL PEGylated 
fibrin groups (p < 0.05). These results suggest that 2D projections in the imaging (xy) 
plane are a reasonable estimate of true network length. However, this similarity is likely 
an incidental product of our vascular networks exhibiting significant growth bias “in-
plane” with imaging; confocal volume aspect ratios ranged from 3:1 to 5:1 (xy-plane:z-
axis). Such anisometric growth bias maximized spatial information in the xy-plane and 
facilitated a near-accurate 2D approximation of network length.  
In culture systems with isometric growth or with anisometric growth that occurs 
“out-of-plane” with imaging, reliable correlation of 2D and 3D measures cannot be 
presumed. To substantiate this claim, we applied our 3D morphological quantification 
method to measure aortic ring outgrowth in 10mg/mL PEGylated fibrin gels. Outgrowth 
lengths plotted in Figure 2.6 show significant disagreement between (all three) 2D 
 30 
estimates and the actual 3D value. We observed no statistically significant difference in 
2D lengths between each of the three planes (xy, xz, yz), suggesting the aortic ring 
approximates an isometric growth pattern. Typically, this ring outgrowth would be 
quantified via manual tracing of a 2D image, similar to the protocol typically entailed by 
the MCB assay. The results of this study suggest that previously reported network lengths 
in fact significantly underestimated the true length of aortic ring outgrowth. 
 
3D morphometry provides more biologically relevant metrics 
As previously mentioned, 2D morphological analysis of vasculature is limited to 
reporting basic metrics such as surface area, perimeter length, and network length. While 
important, these 2D metrics fail to provide a complete picture. For example, studying the 
lumenal architecture of vascular networks necessitates accurate estimates of network 
volume. Volume estimates from current 2D analytical methods require simplifying 
assumptions that could distort or misrepresent the true spatial structure of the vascular 
network. Direct estimates obtained from 3D analysis would overcome such issues and 
provide clearer, more accurate measures. 3D morphological analysis easily provides a 
measure of volume (Figure 2.7A) in addition to network length (Figure 2.5) and other 
basic metrics such as the number of network segments and degree of network branching 
(Figure 2.7B and 2.7C, respectively). Through further studies, a predictive model may 
even be developed to correlate volume with lumen formation. More broadly, quantitative 
morphological outcomes may form the basis of predicting vascular function. 
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Translating qualitative observation into the quantitative domain 
The premise of morphological quantification is to convert qualitative observations 
into numerical values that enable meaningful statistical analysis. In this sense, any one 
metric, especially one derived from 2D analysis, is unable to fully and accurately 
represent the complex morphologies of vascular networks. For example, two networks 
may exist with similar lengths but possess very different morphologies (e.g., short with 
many branches versus long with few branches). Here, we illustrate how a set of 
biologically relevant 3D metrics is able to fully capture the nuances of vascular network 
morphology, thus providing more robust quantitative support for our conclusions 
previously drawn using only qualitative observations. 
 
From confocal images, we observed that (a) PEGylated fibrin produced more 
extensive vascular networks than fibrin only gels, and (b) fibrin PEGylation was more 
influential to vascular network development than fibrin concentration. Network length 
(3D and 2D), volume, and number of segments all trended in agreement with this 
qualitative assessment. ANOVA revealed fibrin PEGylation to be highly significant in 
MSC-derived vascular network formation (volume, p < 0.001; length and segment 
number, p < 0.0001). Post hoc tests confirmed PEGylated fibrin networks had 
significantly longer lengths (Figure 2.8), larger volumes (Figure 2.7A), and more 
segments per network (Figure 2.7B) than fibrin controls. Matched for PEGylation, no 
statistical significant differences were observed among samples with varying fibrin 
concentrations, including the degree of network branching (Figure 2.7C).  
Interestingly, volume and number of network segments (Figures 2.7A and 2.7B, 
respectively) indicated Matrigel networks were similar to those of PEGylated fibrin. 
Network length, on the other hand, suggested a significant difference between the two 
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materials. As previously discussed, the use of a single metric produces misleading 
conclusions, and only the additional context from multiple metrics can provide a full 
picture of the network morphology. Here, the collective metrics suggest Matrigel 
networks are much shorter and broader than PEGylated fibrin networks despite having a 
similar number of branches. 
 
CONCLUSIONS 
Our 3D morphological quantification method was able to numerically capture the 
qualitative observations regarding vascular network development in fibrin-based gels. 
Final numerical outcomes paralleled the original observations: significant experimental 
differences (PEGylation) were highlighted while negligible differences failed to be 
recognized (fibrin concentration). Quantifying complex tissue properties such as 
morphology helps limit the error associated with subjective versus objective measures. 
Minimizing user-based decisions and relying more heavily on semi-automated 
computational approaches further improves objectivity. Additionally, matching the 3D 
nature of complex tissues with an appropriately 3D analytical technique can sharpen the 
accuracy of morphological assessment. As the field of tissue engineering continues to 
progress and produce increasingly complex constructs, methods of construct assessment 
must progress in tandem to ensure our results remain robust and relevant. The method 
described here will hopefully serve as a basic platform to grow more detailed 3D 
quantification approaches.  
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Metric Definition 
Network The tubulogenic outgrowth of one microcarrier bead limited to cell growth directly attached to the microcarrier bead 
Segment A unique path within the tubulogenic outgrowth of one network; each segment has one origin and one terminus 
Volume 
Calculated via cylindrical approximation between adjacent coordinates of 
a segment34; cylindrical volume is assumed to have two radii of unequal 
length 
Degree of 
Branching Ratio of target:seed fiducials for a given network 
3D Length 
Segment length as calculated with 3D distance formula using (x,y,x) 
coordinates of centerlines; distances between adjacent coordinates of a 
segment were summed to achieve one segment length; segment lengths for 
a network were summed to achieve one network length 
2D Length Segment length as calculated with 2D distance formula using either (x,y), (x,z), or (y,z) coordinate pairs 
Table 2.1: List of quantitative metrics and their corresponding conceptual and/or 
mathematical definition. 
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Figure 2.1: Image processing steps in 3D Slicer’s VMTK. Sample shown is from the 
10mg/mL PEGylated fibrin group. (A) Z-projection of the original confocal 
volume using standard deviation of pixel values; (B) Z-projection of the 
enhanced confocal volume after applying Frangi’s vesselness; (C) image 
from (A) with overlay of segmented 3D model in green; (D&E) evolved 
model from (C) shown in the XY- and YZ-planes, respectively; (F) evolved 
model with source and target fiducial placement; (G) Voronoi diagram of 
evolved model; (H) centerlines skeleton extracted from (G). 
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Figure 2.2: Centerline traces of an MCB with tubular outgrowths. Each numbered line 
represents a segment defined by a unique, non-overlapping path; all 
segments together (12 total) represent one network. Similarly, numbers 
correspond with target fiducials while letters correspond with source 
fiducials. 
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Figure 2.3: Confocal z-stack projections. Image stacks for each experimental group were 
captured under 10x objective; shown is a z-projection using the standard 
deviation of pixel values. Segmented 3D models are overlaid in green. Scale 
bar = 200µm. 
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Figure 2.4: Validation of systematic error. X-axis indicates concentration of fibrin in 
mg/mL. Network branches were traced on z-projections of confocal stacks 
using ImageJ’s Simple Neurite Tracer plug-in. Calculated network lengths 
based on our computational method were not significantly different than 
lengths manually traced. However, both methods were able to discern 
significance between vascular networks formed in PEGylated fibrin and 
fibrin controls; bars indicate standard error, * p < 0.05, ** p < 0.01. 
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Figure 2.5: Comparison of 3D and 2D measurement of network length. X-axis indicates 
concentration of fibrin in mg/mL. 2D measures did not reliably agree with 
corresponding 3D values and underestimated network length by as much as 
40%; bars indicate standard error, *p < 0.05. 
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Figure 2.6: Comparison of 3D and 2D measurement of aortic ring outgrowth. (A) 
Confocal z-stack projection of a rat aortic ring with outgrowth in PEGylated 
fibrin. (B) 3D model generated from the image stack represented in (A). (C) 
2D measures significantly underestimated actual 3D values in all three 
planes; bars indicate standard error, *p < 0.05, **p < 0.01. 
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Figure 2.7: Quantification of angiogenesis-related metrics as processed in MATLAB. . X-
axis indicates concentration of fibrin in mg/mL; “PEG” indicates PEGylated 
fibrin and “(-)” indicates fibrin control, (A) Average network volume from 
cylindrical approximation. (B) Average number of segments per network. 
(C) Degree of branching for PEGylated fibrin groups. Due to the lack of 
clear branching, this metric was unable to be calculated for fibrin controls or 
Matrigel groups. In (A) and (B), PEGylated fibrin had significantly higher 
group means than fibrin controls; bars indicate standard error, *p < 0.05, § p 
< 0.001. 
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Figure 2.8: Comparison of PEGylated fibrin and fibrin network lengths as measured in 
3D and 2D. “PEG” indicates PEGylated fibrin and “(-)” indicates fibrin 
control. PEGylated fibrin gels stimulated more extensive MSC network 
formation with significantly longer outgrowth than fibrin controls; bars 
indicate standard error, *p < 0.05, **p < 0.01. 
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Chapter 3: Characterization of biomaterial and cellular changes 
induced by fibrin PEGylation 
OVERVIEW AND AIMS 
Chapter 3 focuses on characterization of both biomaterial properties and cellular 
behaviors as outlined in Aim 2. The morphological pipeline described in Chapter 2 is 
applied in this endeavor. 
 
Aim 2: Determine the impact of fibrin PEGylation on the morphologic and 
phenotypic changes of MSCs.  
Rationale: Fibrin matrices are a common natural polymer in vascular tissue 
engineering but these networks are unable to induce tubulogenesis without 
additional soluble factors. Outcomes aim to characterize cell changes associated 
with biomaterial properties of PEGylated fibrin. 
A. Characterize rheological and diffusional properties of fibrin-based gels. 
B. Assess MSC tubular networks by quantitative morphometry (from Aim 1) and 
verify lumenal space development. 
C. Determine cytoskeletal and integrin components responsible for cell motility 
D. Measure biologic response of MSCs via cell proliferation, protein marker 
expression, and secreted factor production.  
E. Implicate potential mechanisms that link results from 2A and 2B. 
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INTRODUCTION 
Autologous cell-based therapies are a developing strategy to address ischemic 
morbidities and promote revascularization of oxygen- and nutrient-deprived tissue.  
Currently, common targets include sites of acute injury, large or chronic wound beds, and 
critical limb ischemia.1-6 For these applications, the end-goal is to achieve 
revascularization, which is often the rate-limiting step in wound healing.7-10 Establishing a 
robust blood supply better sustains the high metabolic demands of inflammation and 
tissue remodeling and promotes more rapid resolution of the damaged tissue.7 Healing 
outcomes have been further improved when biomaterial gels, foams, or scaffolds are co-
delivered with the grafted stem cells.11,12 These biomaterials serve a threefold purpose: (1) 
to act as a cell delivery vehicle, (2) to enhance and direct stem cell behavior, and (3) to 
serve as bioactive filler that physically and biochemically integrates with local tissues. 
Biomaterials for vascular tissue engineering and wound healing applications 
typically utilize extracellular matrix (ECM) proteins, such as collagen, elastin, 
fibronectin, and laminin.13-17 Fibrin, a clotting protein derived from thrombin proteolysis 
of fibrinogen, is another commonly used natural polymer.12,18 Although ECM components 
are more physiologically abundant, fibrin has a superior ability to stimulate 
neovascularization.19,20 Studies on soft matrix composition have showed that vascular 
network development is directly related to fibrin content and inversely correlated to 
matrix stiffness.17,21-23 Fibrin matrices also stimulate stromal cell production of angiogenic 
paracrine factors, encouraging innate neovascularization mechanisms of the host 
vasculature. In stem cell populations, fibrin content has been associated with upregulation 
of endothelial-like genes.24 Despite the bioactive advantages of fibrin matrices, pure 
fibrin is rapidly degraded in vivo via natural fibrinolytic cascades, which limits its 
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therapeutic window. Hence, fibrin-composites have gained popularity as a means of 
mitigating fibrin degradation and fine-tuning biomaterial properties.21,25 
Our group has previously reported on PEGylated fibrin as a natural-synthetic 
polymer composite that promotes spontaneous network formation of encapsulated bone 
marrow-derived mesenchymal stem cells (MSCs), without added soluble factors. 26,27 
Here, PEGylation slows fibrinolysis and extends the therapeutic window of MSCs 
localized within the matrix. Additionally, bone marrow-derived MSCs serve as an readily 
available autologous progenitor population that are responsive to substrate cues28 and 
have a proven history of enhancing angiogenic activity and wound closure.3,6,11,29 While 
we have previously observed a dramatic increase in vascular morphogenesis of MSCs in 
PEGylated fibrin gels (compared to pure fibrin gels),30 the full breadth of differences in 
cellular behavior has not yet been characterized and nor have the underlying mechanisms. 
Understanding how PEGylation changes biomaterial properties is critical to 
understanding why MSC network development is significantly improved. Furthermore, 
gaining a clearer understanding of this cell-gel system will facilitate a more targeted 
clinical context for its implementation. 
The studies presented here aim to characterize the biophysical properties of 
PEGylated fibrin gels and subsequent cell mechanisms of motility and relevant biological 
behavior, including production of secreted factors and markers of an endothelial 
phenotype. Experiments were designed to highlight differences between PEGylated fibrin 
and fibrin matrices as well as implicate potential mechanisms that motivate MSC 
vascular morphogenesis. 
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MATERIALS AND METHODS 
Materials 
Low-glucose Dulbecco’s modified Eagle’s medium (DMEM), phosphate buffered 
saline (PBS), fetal bovine serum (FBS), and Gluta-MAX™-I (100x) were purchased from 
Invitrogen (Carlsbad, CA). Penicillin-streptomycin and trypsin/ethylenediaminetetraa-
acetic acid were purchased from ATCC (Manassas, VA). Sigma-Solohill microcarrier 
beads (MCBs) coated in porcine collagen were obtained from Sigma-Aldrich (St. Louis, 
MO) as well as fibrinogen and thrombin from human plasma. Linear homo-difunctional 
succinimidylglutarate polyethylene glycol (PEG-(SG)2, 3400 Da) was  purchased from 
NOF America (White Plains, NY). 
 
Cell culture of mesenchymal stem cells 
Human bone marrow-derived mesenchymal stem cells (hMSCs) from Lonza 
(Basel, Switzerland) were cultured according to manufacturer specifications with growth 
medium in tissue culture-treated plastic flasks (Corning, Corning, NY) at 5000 cells/cm2. 
Growth medium consisted of DMEM supplemented with 10% FBS, 1% penicillin-
streptomycin, and 2mM GlutaMAX™-I. Cells were tested by the manufacturer for 
trilineage differentiation potential and for positive expression of CD105, CD166, CD29, 
and CD44; cells were negative for CD14, CD34, and CD45. Population purity was 
greater than 95%. All cell cultures were maintained at 37°C and 5% CO2. 
 
Cell seeding of microcarrier-beads 
hMSCs were seeded on MCBs according to our previously described protocol,30 
based on the modified bead-outgrowth assay developed by Nakatsu and Hughes.31,32 
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Briefly, MCBs were suspended at 2 mg/mL in PBS, autoclaved, and stored at 4°C before 
use. Prior to seeding, MCBs were distributed as 4mg aliquots into FACS tubes and 
briefly centrifuged into a pellet to remove the PBS. Growth media was added for 1h to 
prime MCBs for cell seeding, which was then removed immediately before adding cells. 
hMSCs at passages 4-6 were trypsinized, centrifuged into a pellet, and re-suspended at a 
minimum concentration of 1.4×105 cells/mL growth media. Cells were added to FACS 
tubes of MCBs for a final concentration of 7.0×104 cells/mg MCB and a total of 2mL 
growth media per FACS tube. Cells and MCBs were gently resuspended every 30min for 
the first 4h to evenly coat MCBs with cells. Seeded MCBs were strained through a 70µm 
mesh and rinsed with PBS to remove any unattached cells. Finally, MBCs were 
resuspended in 300µL growth media/mg MCB. 
 
Three-dimensional gel culture in vitro 
Gel fabrication followed our previously described protocol for enzymatically 
crosslinked PEGylated fibrin and fibrin gels.26 Human fibrinogen was solubilized in PBS 
(without calcium or magnesium, pH 7.8) at three different concentrations: 80, 60, and 40 
mg/mL. PEG-SG2 was similarly dissolved in PBS at three different concentrations: 8, 6 
and 4 mg/mL. The PEG-SG2 concentrations correspond with a 10:1 molar ratio of 
reactive groups to each fibrinogen solution. Human thrombin was reconstituted in 
nanopure ddH2O to 100U/mL, which was further diluted to 25U/mL with 40mM CaCl2. 
Gel components were passed through 0.22µm filters for sterility before use. Gels with 
1mL total volumes were fabricated in 12-well plates and those with 0.5mL total volumes 
in 24-well plates. Gel components were mixed in the following order using the same 
volumetric ratio: 1 fibrinogen: 1 PEG-SG2: 2 seeded MCBs: 4 thrombin. Gelation was 
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finalized at 37°C for 15min before rinsing with PBS (with calcium and magnesium), 
followed by growth media rinses at 5min, 10min, 30min, and 1h to remove cytotoxic 
unreacted PEG-SG2. Gel culture was carried out to Day 7 with growth media unless 
otherwise specified.  
 
Small molecules for functional assays 
For some experimental groups, small molecules, proteins, or peptides were added 
to culture media. Table 3.1 lists each molecule, the concentration used, the experimental 
study in which it was applied, and the manufacturer’s information. 
 
Hypoxic culture 
In addition to normoxic culture conditions, MSCs in PEGylated fibrin were also 
cultured under 1% O2 and 2% O2 using a hypoxia chamber (Stemcell Technologies; 
Tukwila, WA), generously loaned to us from Dr. Aaron Baker. Hypoxic gas mixes were 
composed of 5% CO2, 1% or 2% O2, and N2 balance (Praxair; Danbury, CT). Cell 
cultures were sealed inside the hypoxia chamber with a petri dish of water for humidity. 
The chamber was purged with a hypoxic gas mix for 5min and then purged again 90min 
later to evacuate any residual oxygen content from the culture media. Thereafter, the 
chamber was purged every 48h to maintain hypoxic cultures unless opened for assay 
endpoints. 
 
Rheology 
Gels were prepared without cells by substituting PBS for the MCB volume during 
gel preparation. Gels were formed in 40mm diameter nonstick molds for a parallel plate 
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rheometer configuration and were kept hydrated with PBS prior to and during testing. 
Strain sweeps were measured from 0.1-2.5% at 15 rad/s at a plate temperature of 37°C. 
Storage and loss moduli were reported for statistical comparison at 1% strain. 
 
Cryogenic scanning electron microscopy 
Cell-free gels were prepared in small-volume molds and kept hydrated in PBS 
(with calcium and magnesium). Gels were briefly rinsed in ddH2O before mounting on a 
cryogenic SEM stage with carbon tape. Mounted gels were then snap-frozen in liquid 
nitrogen and fractured with a scalpel to expose cross-sectional structures. Gels were 
transferred to the cryo prep unit within a vacuum cryo transfer shuttle (Leica EM 
VCT100) to minimize crystal formation from air exposure. In the prep unit (Leica EM 
MED020), the stage temperature was raised from -140°C to -110°C to sublimate water 
crystals from the gels. Samples were then sputter coated with palladium and shuttle-
transferred to the SEM for imaging. The SEM stage was kept at -120°C to -123°C for the 
duration of imaging. 
 
Diffusional characterization 
Syringes (without the plunger) were used as molds for containing fibrin or 
PEGylated fibrin gels and the test solute. Cell-free gels (500µL volume) were formed at 
the 0cc demarcation of the syringe barrel, gelled to completion at 37°C, and rinsed with 
an equal volume of PBS. After the PBS was aspirated, the slip-tips of the syringes were 
carefully removed to expose the gel bottoms. Removal of the slip-tips ensured that 
diffusivity of the test solute was limited by the gel and not by capillary resistance of the 
solvent through the syringe. Syringes were vertically fixed in place and 500µL of 
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2.5mg/mL 10kDa dextran-Texas Red conjugate (Molecular Probes; Eugene, OR) was 
added directly on top of the gels. While fluorescence was not utilized, the purple 
appearance of Texas Red dye provided clear visualization of the dextran. Time-lapse 
photos of dye diffusion were taken every 15min for 7h. 
 
Fluorescent cell staining for morphological quantification 
On day 7 of gel culture, samples were rinsed six times with PBS (with calcium 
and magnesium) for 15min each. Calcein AM (Invitrogen; Carlsbad, CA), a live-cell 
cytoplasm stain, was added at 10µM for 1h. Samples were rinsed four times with PBS 
every 5min and then fixed with 4% neutral-buffered formalin for 30min. Finally, gels 
were briefly rinsed with 3 volumes of PBS to remove residual fixative and stored at 4°C 
overnight for imaging the next day. 
 
Fluorescent cell staining for visualizing vacuolization 
Texas Red-conjugated dextran (10kDa; Molecular Probes; Eugene, OR) was 
added to the media of gel culture as a cell-impermeable dye that could only be 
intracellularly localized through pinocytic uptake. For one-week endpoint cultures, 
1.25mg/mL of dextran was added on Day 4; for two-week endpoint cultures, dextran was 
added on Day 7 and Day 11. After cultures were terminated, MSCs were fixed and 
additionally stained with FITC-phalloidin (F-actin) and DAPI (nuclei). 
 
Two-photon microscopy 
Fluorescent z-stacks were collected of MSC outgrowth from individual 
microcarrier beads with an Ultima Multiphoton Microscopy System (Prairie 
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Technologies; Middleton, WI).  Two-photon excitation was achieved with a tunable 
Ti:sapphire laser (Spectra-Physics Mai Tai HP; Newport; Irvine, CA) set to 720nm under 
a 10x water-immersion objective. Z-slice thicknesses were adjusted to maintain isometric 
voxel dimensions. A thickness of 500-700µm was imaged along the z-axis for each 
image stack. 
 
Three-dimensional morphological quantification 
Image processing and three-dimensional morphological quantification followed 
our recently described method.30 As before, z-stacks were preprocessed in ImageJ 
(Release 1.2.4; ImageJ Plugin Project) and exported as Visualization Toolkit (.vtk) files 
and loaded into 3D Slicer (Release 3.6, 64-bit Linux), an open-source program for 
MRI/CT analysis. The Vascular Modeling Toolkit in 3D Slicer was used for image 
segmentation and 3D model generation. Centerline tracings of 3D models were exported 
as large data clouds of x,y,z coordinates with corresponding radii; the measured radius 
represented the model’s maximum cross-sectional diameter at each coordinate point. The 
data cloud was processed in MATLAB (Release 2008a for Macintosh) into quantitative 
metrics that describe relevant attributes of network development: total network length, 
volume, and number of branches (per MCB). 
 
Cell proliferation 
The CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega; 
Madison, WI) was used to quantify the cell content of gels. On days 1, 3, 5, and 7 of gel 
culture, the culture supernatant was removed and saved for future protein analysis. Fresh 
growth media + 20% (v/v) CellTiter 96® solution was then added for 4h. Supernatants 
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were thoroughly homogenized before transferring 200µL samples in triplicate to a 96-
well plate. Absorbance was measured at 490nm with a microplate reader (BioTek 
Synergy HT Multi-Mode Microplate Reader; Winooski, VT). 
 
Secreted protein detection with ELISA 
Quantikine ELISA kits (R&D Systems; Minneapolis, MN) were procured for 
VEGF, matrix metalloproteinase-2 (MMP-2), and MMP-9 proteins. Supernatant collected 
from cell proliferation samples were assayed according to the manufacturer’s 
instructions. Optical density was measured at 490nm. Secreted protein quantities were 
normalized to cell number using the results of the matched-sample MTS assay. 
 
Cellular protein detection with western blot analysis 
Cells in gel matrices were lysed with RIPA buffer (Santa Cruz Biotechnology; 
Dallas, TX) and homogenized for 30s with a soft tissue grinder. Cell-gel lysates were 
passed through a 21-gauge needle 20× for further homogenization and solid gel remnants 
were removed through sample centrifugation at 14000×g for 10min at 4°C. The 
supernatants were denatured in a reducing buffer of Laemmli sample buffer with 5% β-
mercaptoethanol at 95C for 5min. Denatured samples were separated with 10% mini-
Protean® TGX™ precast gels (Biorad; Hercules, CA) at 20µg protein per gel lane and 
blotted onto PVDF membranes. Membranes were blocked for 1h at room temperature 
with 5% (w/v) nonfat milk in TBST and then incubated overnight with a primary 
antibody at 4C. Membranes were then rinsed with TBST 3× for 5min each and incubated 
with an HRP-conjugated secondary antibody for 1h at room temperature. After a second 
set of TBST rinses, 3mL of SuperSignal West Dura Chemiluminescent Substrate (Pierce 
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Thermo Fisher Scientific; Rockford, IL) was added per blot for 5min prior to image 
capture with a FluorChem CCD system (ProteinSimple; Santa Clara, CA). 
Chemiluminescent signal was quantified with AlphaView software for statistical analysis. 
For a list of antibodies and their dilutions, refer to Table 3.2. 
 
Statistical analysis 
A one- or two-way analysis of variance was used to determine significance 
between fibrin concentrations and PEGylation. Where significance was found, post-hoc 
tests were performed to further determine specific relationships of statistical significance. 
Tukey’s correction for multiple comparisons was applied where appropriate. P-values 
less than 0.05 were considered statistically significant. All statistical tests were completed 
in Prism (Version 6.0 for Mac OS X; GraphPad, La Jolla, CA). 
 
RESULTS AND DISCUSSION 
Fibrin PEGylation changes biophysical gel properties 
Rheological properties of fibrin and PEGylated fibrin were compared across three 
increasing concentrations (5-10mg/mL fibrin), using a parallel plate rheometer (Figure 
3.1A). At 1% strain, the storage modulus indicated a significant increase in gel elasticity 
as fibrin concentration increased. This trend suggests that gel elasticity of both fibrin and 
PEGylated fibrin is governed by fibrin crosslinking, which is reflective of total fibrin 
content. Significant differences between the storage moduli of fibrin and PEGylated 
fibrin gels were only observed at 10mg/mL fibrin. 
The loss modulus indicated no significant changes in viscous properties between 
fibrin and PEGylated fibrin, nor between fibrin concentrations within each gel type. 
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However, general trends showed the loss modulus only increased with fibrin 
concentration in unmodified fibrin gels, remaining unchanged across PEGylated fibrin 
gels. In fact, the loss moduli for all PEGylated fibrin gels were comparable to the loss 
modulus of the 5mg/mL unmodified fibrin group. This loss modulus behavior can be 
attributed to the bound versus free water content of each gel system. Bound water 
contributes to bulk elastic properties of biopolymers whereas free water will flow and 
contribute to the energy dissipation imparted by the viscous component.33 This 
information suggests that PEG buffers the increasing free water content of fibrin as the 
total water absorption capacity rises with concentration. In unmodified fibrin, the ratio of 
unbound:free water remains the same since no such buffer exists; thus, we see an increase 
in loss modulus in tandem with the storage modulus. 
Morphological analysis of gel cross-sections highlighted more dramatic changes 
between the two materials. Under cryo-SEM, fibrin gels had a characteristic fibrosity that 
resembled a heterogeneous sponge-like structure (Figure 3.1B and 3.1D). This fibrosity 
yields the overall whitish, opaque appearance of fibrin gels. PEGylated fibrin, however, 
had more solid amorphous regions (Figure 3.1C and 3.1E, “a”) interspersed with fibrous 
layers (Figure 3.1E, “f”), giving these gels a more optically clear appearance. 
The functional impact of these morphological differences between fibrin and 
PEGylated fibrin was illustrated with a simple diffusional study. Here we used time-lapse 
photography to track liquid filtration and diffusion of a 10kDa dextran-Texas Red 
conjugate in both fibrin and PEGylated fibrin gels (Figure 3.1F). After only 2.5h, the 
dextran completely diffused through the fibrin gel and can be clearly seen in the filtrate. 
Along with the fast-moving dye front, we also observed a significant drop in the liquid 
level above the fibrin gel, such that >80% of the liquid had completely filtered through 
the gel by 7h. PEGylated fibrin, however, showed approximately 20-25% dextran 
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penetration at 2.5h and approximately 50% after 7 hours, with the liquid level unchanged 
from 0h. 
Based on these material characterizations, we find that fibrin PEGylation is 
uniquely responsible for a number of biologically-relevant material changes. While 
PEGylation can result in a lower elastic modulus at higher fibrin concentrations, initial 
work from our group showed that this trend can vary depending on the molecular weight 
and reactivity of the PEG used.26 Additionally, the amorphous regions in PEGylated 
fibrin (that were lacking in fibrin) can be attributed to a shift in molecular aggregation 
kinetics. Literature on PEG-fibrin conjugates suggest that PEGylated fibrin products 
maintain a cylindrical fibrin core with a hydrodynamic radius dictated by linear PEG 
tails.34 The PEG-induced hydrodynamics disrupt tertiary and quaternary protein folding 
without damaging the bioactivity of fibrin’s secondary structure. Furthermore, PEG-
fibrin conjugates have intensified light scattering upon gelation, indicating an increase in 
inhomogeneities from the aggregate solution to gel transition. These features of 
amorphous gel packing are the most pronounced physical change introduced by fibrin 
PEGylation; the slowed dextran diffusion can be subsequently linked to the physical 
transformation from a highly porous, fibrous matrix to an amorphous, pseudo-fibrous gel.  
Slowed diffusivity in PEGylated fibrin gels will have a direct impact on nutrient 
and oxygen diffusion for encapsulated cells. While cell encapsulation will impart some 
degree of hypoxic stress by virtue of transport dynamics,35 the diffusional properties of 
PEGylated fibrin are likely to induce a higher degree of hypoxic stress than fibrin alone. 
Studies on oxygen transport in fibrin-based matrices at 30mg/mL fibrin had 10× slower 
oxygen diffusion than water, which generated a hypoxic scaffold core.36 Extrapolating 
this data to our system, 10mg/mL fibrin gels may have diffusion kinetics up to 3× slower 
than that of water. Since PEGylated fibrin is empirically more diffusion-limited than 
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fibrin, we can infer that PEGylated fibrin matrices diffuse oxygen at a rate at least 3× 
slower or more than water, though likely more. 
 
MSCs in PEGylated fibrin develop networks with lumenal space 
A defining step in endothelial network development is the coalescence of large 
vacuoles into an intercellular lumenal space.37-40 In vascular development, lumens are 
known to form through two distinct mechanisms: cell hollowing and cord hollowing.41,42 
Cell hollowing is characterized by a chain of individual cells forming large intracellular 
vacuoles through pinocytic uptake of interstitial fluid. These large vacuoles form 
intercellular fusions, creating a seamless continuous tube. Cord hollowing is a newer 
paradigm for vascular development where multicellular columns (i.e., cords) are 
polarized by VE-cadherin-dependent mechanisms into apposing cellular walls. During 
polarization, pinocytosed vesicles are trafficked towards the apical axis and fuse.43 Cell 
boundaries along the apical axis repel and separate, further creating a central extracellular 
lumen. Tubes formed by cell hollowing generally have narrower diameters than those 
formed by cord hollowing due to fewer cells contributing to the overall structure. Both 
mechanisms require subsequent lumenal expansion to accommodate blood flow.41,42 
Confirmation of lumenal development with standard two-dimensional light 
microscopy is unreliable; these images are unable to unequivocally differentiate between 
flat, tube-like networks and true voluminous tubes. Therefore, we opted for z-stack image 
collection and 3D model generation with 3D Slicer to fully capture evidence of 3D 
lumenal space formation. Based on a study by George Davis’s group on endothelial 
network development,44 we added 10kDa dextran-Texas Red conjugate to the gel culture 
media to label pinocytosed vesicles and developing lumenal spaces. Networks were co-
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stained with FITC-phalloidin (F-actin) and DAPI (nuclei) and imaged with fluorescent 
microscopy. Localization of large, intracellular compartments containing dextran-Texas 
Red indicated pinocytic dye uptake (Figure 3.2). Dextran-containing vesicles spanning 
multiple cell lengths further suggest intercellular vacuole fusion. Given the distribution of 
non-overlapping nuclei and narrow tube diameter, this pattern of dye uptake is highly 
reflective of cell-hollowing lumen assembly. This finding substantiates our claims that 
MSC networks are in fact tubular and not merely flat projections of cell bodies. 
 
Vascular morphogenesis of MSCs is mediated by tubulin assembly and integrin 
binding 
In endothelial vascular morphogenesis, network assembly and lumen formation 
rely on generating intracellular tension via cytoskeletal assembly and traction via 
integrin-mediated adhesions.45 Specifically, endothelial networks are most dependent on 
tubulin polymerization, concomitant with matrix-appropriate integrin expression.46 In 
fibrin matrices, αvβ3 and α5β1 are preferentially expressed and have a known affinity 
for RGD binding motifs.47,48 For MSCs in PEGylated fibrin, network formation was 
moderately disrupted by cytochalasin B inhibition of actin assembly and significantly 
blocked by colchicine inhibition of tubulin dynamics (Figure 3.3A, C, and D). Similarly, 
when cyclic GRGDSP was added, MSCs were also unable to migrate off of the 
microcarrier bead (Figure 3.3E); MSCs cultured with the cyclic GRGESP control 
continued to form normal networks that were statistically similar to non-doped 
PEGylated fibrin controls (Figure 3.3F and B). The ability of cyclic GRGDSP to out-
compete matrix binding motifs indicates that a) MSCs are binding RGD-based matrix 
sites and b) that MSC have no alternative means of generating traction forces within 
PEGylated fibrin aside from integrin-mediated events.  
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These results, though unsurprising, were necessary to verify that MSCs both 
parallel the cellular mechanics of endothelial vascular morphogenesis and also exhibit 
normative, non-malignant behavior. Integrin-independent motility is typical of immune 
cell populations.49,50 However, in mesenchymal populations, deviation from integrin-
dependent migration can signal a mesenchymal-amoeboid transition, which is linked to 
aggressive cancer metastases.51 We can assume, then, that the ability of MSCs to coalesce 
networks in PEGylated fibrin (and not fibrin) is the result of normative cell mechanisms 
guided by matrix cues and not the emergence of a malignant phenotype.  
 
PEGylated fibrin increases production of angiogenic factors and expression of 
endothelial markers 
We have previously reported on morphological differences between MSCs 
cultured in fibrin and PEGylated fibrin, particularly that cells in fibrin appear highly 
proliferative and migratory while those in PEGylated fibrin form continuous tubular 
networks.30 With a tetrazolium-based metabolic assay, we quantified the growth kinetics 
of MSCs in both gels. Figure 3.4A clearly illustrates the rapid exponential growth of 
MSCs in fibrin and slower (more linear) growth of MSCs in PEGylated fibrin. The 
divergence in growth kinetics was significantly evident by Day 3. Interestingly, we 
observed the opposite matrix-proliferation relationship in previous work: MSCs were 
more proliferative in PEGylated fibrin than in fibrin matrices.26 However, a number of 
variables in our gel materials and protocol have changed since that first report. We now 
use human instead of porcine fibrinogen, PEG succinimidyl glutarate instead of PEG 
benzoyltriazole carbonate, and PEGylate fibrinogen in PBS instead of TBS (pH 7.8). 
Additionally, porcine fibrin matrices rapidly collapsed during culture, limiting MSC 
growth to the gel surface. The premature collapse of fibrin matrices may have 
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underrepresented the true proliferation capacity of these gels, skewing the data. Present 
fibrin matrices from human fibrinogen do degrade more rapidly than PEGylated fibrin 
matrices but do not experience catastrophic collapse. Thus, present data is more likely to 
accurately reflect MSC proliferation in fibrin, but past and present data on PEGylated 
fibrin is believed to be consistent. 
Stem cell proliferation also has a well-known bimodal correlation with stem cell 
differentiation. The slower rate of proliferation in PEGylated fibrin may allow for an 
increase in differentiation behavior. In support of this possibility, MSC secretion of 
angiogenic factors and expression of endothelial markers were significantly elevated in 
PEGylated fibrin gels over fibrin controls. ELISA analysis of secreted factors showed an 
increase in early production of VEGF and later production of MMP-2 (Figures 3.4D and 
3.4E, respectively) in PEGylated fibrin MSCs. Additional analyses of cellular markers 
indicated that MSCs in PEGylated fibrin also express higher levels of vWF and VE-
cadherin proteins (Figures 3.4B and 3.4C, respectively), which are characteristic of an 
endothelial lineage. The vascular morphology driven by PEGylated fibrin matrices 
clearly extends to complementary MSC development of endothelial functions and 
phenotypic features.  
Other groups have reported similar combinations of MSC endothelial-like 
behavior as well. In early studies, VEGF was initially used as a morphogen to drive MSC 
differentiation towards an endothelial lineage. By adding 50ng/mL VEGF to the culture 
media, MSCs began expressing a number of endothelial markers after seven days in 
culture, including vWF, VE-cadherin, VEGF receptors 1 and 2, and VCAM-1.52 Fibrin-
based substrates, with angiogenic growth factors, were also able to induce MSC 
endothelial marker expression in vitro. However, when these substrates were tested in in 
vivo models of ischemia and wound healing, the therapeutic value of MSCs was primarily 
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derived from their paracrine production of VEGF, hepatocyte growth factor (HGF), 
transforming growth factor (TGF)-β1, and a milieu of other cytokines.6,53,54 These factors 
encourage local proliferation and survival of endothelial cells and curb excessive 
inflammation.29,55,56 In our work here, VEGF production is likely acting as both an 
endothelial morphogen and an indicator of angiogenic paracrine activity; fibrin may cue 
initial VEGF production, but once produced, endogenous VEGF enables a positive 
feedback mechanism that perpetuates further endothelial development of MSCs.56 
Matrix metalloproteinases are another critical component of vascular network 
development. In vitro models of angiogenesis and vasculogenesis have implicated MMPs 
as necessary for precursor development of vascular guidance tunnels and later lumenal 
space formation.40,57,58 However, work by Davis et al suggests that overly aggressive 
matrix degradation prevents stabilization of neovascular sprouts,59 and this MMP-laden 
environment can culminate in a chronic wound.60 MMP-2, which is cleaved and activated 
by MT1-MMP (i.e., MMP-14), is a contributing factor to fibrinolytic mechanisms of cell 
motility.61,62 Furthermore, MMP-2 has a co-dependent regulatory relationship with 
VEGF: VEGF can stimulate an increase in MMP-2 production;63 similarly, knockdown of 
MMP-2 can abrogate VEGF secretion via αvβ3-mediated phosphatidylinositol 3-kinase 
(PI3K)/HIF-1α signaling pathways.64 In PEGylated fibrin, MSCs secreted elevated levels 
of VEGF at early time points, followed by elevated levels of MMP-2. Others have also 
observed maximum MMP-2 expression on day 7.62 The literature on these two molecules 
suggests that later elevation of MMP-2 may be a direct response to elevated VEGF. Thus, 
increased VEGF expression further perpetuates the development of MSC vascular 
morphogenesis. 
The biological impact of fibrin PEGylation on MSC behavior was made further 
evident by the significant upregulation of endothelial phenotypic markers, vWF and VE-
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cadherin, over fibrin controls. In endothelialized vasculature, vWF mediates hemostasis 
via platelet adhesion as well as angiogenesis through regulation of angiopoietin (Ang)-2 
levels.65,66 Strong expression of vWF and presence of Weibel-Palade bodies are therefore 
considered an important phenotypic factor in evaluating endothelial functionality. 
Similarly, VE-cadherin provides intercellular junctions that regulate vascular 
permeability and establish apical/basal cell polarity.67,68 MSCs have previously been 
observed to express both in vascular tissue engineering models. Interestingly, VE-
cadherin expression is known to fluctuate indirectly with MMP-2 and MMP-9 activity.69 
This evidence suggests that maximum VE-cadherin expression in PEGylated fibrin MSCs 
is likely to occur sometime after day 7, given MMP-2 activity is at its peak. Future 
studies that evaluate later time points would help inform this association. 
 
Perturbing the VEGF-hypoxia axes modulates MSC tubulogenesis in PEGylated 
fibrin 
Physiologically, tissues greater than 2mm thick are prone to hypoxic necrosis 
unless a vascular supply is able to intervene, and capillary diffusion is typically limited to 
distances of 200µm or less.70,71 In vitro, studies have demonstrated that encapsulated cells 
will experience some degree of hypoxia even when cultured under normoxic 
conditions.35,36 More recently, studies have focused on hypoxic culture of MSCs as a 
means of prolonging their undifferentiated state and encouraging more normative 
physiological programs;72 this work has been especially relevant to bone marrow-derived 
MSCs since the bone marrow niche is considered a mildly hypoxic environment.73-77 
However, under ischemic-related hypoxic stress (approximately 1-2% O2),78 the 
angiogenic programming of MSCs can be activated as part of the natural wound healing 
response.79,80 
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From our material characterization studies, the significant diffusional limitations 
found in PEGylated fibrin prompted further investigation of hypoxia as a previously 
overlooked matrix cue in MSC vascular morphogenesis. Incidentally, hypoxia-mediated 
pathways can also regulate VEGF and MMP-2 production as well as VE-cadherin 
expression.81,82 Here we stimulated both VEGF and hypoxia pathways and evaluated 
MSCs in PEGylated fibrin for a heightened vascular morphogenic response. 
We found that soluble VEGF had no mitogenic effects on MSCs in PEGylated 
fibrin, nor did it elicit an increase in MMP-2 production (Figures 3.5A and 3.5E, 
respectively). In fact, by Day 7, the VEGF group had significantly fewer MSCs than the 
control group. Endogenous VEGF production could not be accurately quantified in this 
case due to the magnitude of added soluble VEGF overshadowing any measurable 
changes. VEGF-stimulated MSC networks were morphologically shorter than the 
PEGylated fibrin control (Figure 3.5C, F, and E), likely associated with the decrease in 
cell number. Despite VEGF being a potent vascular morphogen, a recent paper 
demonstrated a similarly lack of VEGF sensitivity in MSC monolayers. In monolayer, 
addition of VEGF did not result in further upregulation of endothelial gene expression 
over high-density cell culture conditions.83 However, concentrations of 50ng/mL or 
higher did induce stronger MSC expression of Ephrin-B1, suggesting high doses of 
VEGF can play a role in determining arterial cell fate.83 They postulated that their 
results—which may apply to our results as well—culminated from oversaturation of 
VEGF receptors; endogenous levels of VEGF in PEGylated fibrin may be sufficient for 
maintaining activation of MSC vascular pathways and adding further VEGF is merely 
unproductive. This insensitivity further suggests that MSCs are producing VEGF as a 
paracrine factor for auxiliary cell recruitment, rather than autocrine self-promoting 
differentiation. 
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Cobalt chloride, a chemical stabilizer of hypoxia inducible factor 1-alpha (HIF-
1α),84,85 also failed to increase MSC proliferation (Figure 3.5A), VEGF and MMP-2 
production (Figures 3.5D and 3.5E, respectively), and network formation (Figure 3.5C, 
G). While we could have chosen a higher concentration of cobalt chloride, we were 
limited by dose-dependent cytotoxicity. Increasing HIF-1α stabilization with more cobalt 
chloride may have resulted in a stronger HIF-mediated improvement in MSC vascular 
outcomes, but long-term cultures (> 48h) would have experienced dramatic 
cytotoxicity.86 Hence, we opted for a mild-to-moderate concentration of 75µM cobalt 
chloride, which is commonly found in commercial lysates marketed as HIF-1α positive 
controls. Furthermore, hypoxia mimetics such as cobalt chloride and desferrioxamine 
have been shown to incompletely activate relevant downstream effectors of HIF-1α.87-89 
These inactive effectors may be vital to HIF-mediated vascular morphogenesis, 
underlying the moot result observed in this MSC group. 
True hypoxia, however, with 1% oxygen had a significant impact on both cell 
proliferation and protein production;75,77 minimal impact was observed in vascular 
network formation (Figure 3.5C, H). MSCs cultured under hypoxic stress in PEGylated 
fibrin exhibited markedly slower cell proliferation (Figure 3.5A). Conversely, their 
production of VEGF and MMP-2 proteins was elevated for all seven days of culture 
(Figures 3.5D and 3.5E, respectively), which is a well-documented effect of hypoxic 
stress.73,76 Constitutively induced HIF-1α expression, without hypoxia, is also known to 
activate the paracrine secretion of angiogenic factors, supporting the idea of HIF-
mediated induction of angiogenesis. Though hypoxic networks were statistically similar 
in length to controls, the data trends suggest these networks may be at the brink of 
downsizing. Given the significantly slowed MSC proliferation under 1% O2, we find it 
unsurprising that hypoxic networks would tend towards the shorter end of the normal 
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developmental spectrum. Fewer cells in the gel mean fewer cells contributing to network 
size. The limited cell growth also suggests that MSCs may be at their “stress limit” and 
the low oxygen tension is metabolically hindering cell growth. This theory was 
confirmed by measuring MSC proliferation under 2% O2, where cell numbers returned to 
levels comparable to controls (Figure 3.5B). Other studies have indicated that hypoxic 
stress has a biphasic impact on cell survival: mild hypoxia (1-2% oxygen) induces an 
advantageous rescue response whereas more severe hypoxia maximizes HIF-1α 
expression but results in slowed proliferation or even significant cell death.75,90 Slowed 
MSC proliferation may alternatively be the result of a normal lag phase experienced at 
early time points of hypoxic exposure. Overall, enhanced angiogenic behavior under 1% 
O2 coupled with the previously discussed diffusional limitations of PEGylated fibrin 
strongly implicate hypoxic stress as a relevant mediator of MSC vascular morphogenesis. 
 
CONCLUSIONS 
PEGylated fibrin has a unique ability to promote MSC vascular morphogenesis 
without the typical use of soluble factors. By relying solely on matrix cues, we have the 
potential to simplify the clinical translation of MSC-based ischemic therapies and 
improve their utility. The barrier to this implementation has been our lack of thorough 
understanding regarding mechanisms of PEGylated fibrin-induced MSC vascular 
morphogenesis. Here we were able to highlight changes in both physical material 
properties and biological cell outcomes that arise from fibrin PEGylation. We found that 
PEGylated fibrin is significantly diffusion-limited compared to pure fibrin matrices. The 
subsequent increase in MSC production of paracrine and proteolytic factors along with 
endothelial marker expression can therefore be linked directly to this hallmark 
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characteristic. However, MSCs in fibrin were also capable of these behaviors, just to a 
lesser extent. Most interesting, though, was the lack of MSC sensitivity to an added 
VEGF stimulus. In contrast, when PEGylated fibrin matrices were cultured under 
hypoxic conditions, we observed a further increase in secreted factors, despite minimal 
change in morphology. MSC sensitivity to hypoxic stress suggests that this pathway may 
be active during vascular morphogenesis. While we cannot rule out the importance of 
fibrin-related bioactivity and influence, these results give us cause to further investigate 
HIF-mediated mechanisms as a potential underlying source of PEGylated fibrin’s 
increased activity. 
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Molecule Concentration Study Manufacturer 
Cyclo-GRGDSP 500 µg/mL MIC-axis AnaSpec 
Cyclo-GRGESP 500 µg/mL MIC-axis AnaSpec 
Cytochalasin B 0.1 µM MIC-axis Sigma-Aldrich 
Colchicine 0.1 µM MIC-axis Sigma-Aldrich 
Human VEGF-165 50 ng/mL HIF-axis BioLegend 
Cobalt chloride 75µM HIF-axis Fisher Scientific 
Table 3.1: List of small molecules for functional inhibition assays. MIC-axis: matrix 
integrin cytoskeleton axis, Figure 3.3. HIF-axis: hypoxia inducible factor 
axis, Figure 3.5. 
 
 
 
 
Antibody target 1°/2° Dilution Manufacturer 
von Willebrand factor primary 1:1000 Abcam (ab6994) 
VE-cadherin primary 1:700 Abcam (ab33168) 
β-actin primary 1:1000 Abcam (ab75186) 
Rabbit IgG secondary 1:5000 Santa Cruz Bio (sc-2004) 
Table 3.2: List of polyclonal (rabbit) primary and (goat) secondary antibodies used for 
western blot detection of cellular proteins. Antibodies were diluted in 
blocking buffer (5% nonfat milk in TBST). 
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Figure 3.1: Characterization of fibrin and PEGylated fibrin gel properties. Abbreviations: 
10F, pure fibrin at 10mg/mL fibrin; 10P, PEGylated fibrin at 10mg/mL 
fibrin. (A) Rheological analysis showed comparable elastic properties, 
except for at the highest fibrin concentration of 10mg/mL. No measurable 
differences were observed between loss moduli. (B-E) CryoSEM of 
fractured gel cross-sections showed that fibrin PEGylation introduces 
amorphous regions into the gel. Images (D) and (E) are magnified views of 
the insets from (B) and (C), respectively. (F) Time-lapse photography: 
diffusion of 10kDa dextran-Texas Red conjugate in PBS was significantly 
slower in PEGylated fibrin than fibrin. *p < 0.05, versus fibrin control. 
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Figure 3.2: Lumen development of MSC networks in PEGylated fibrin. (A) Calcein AM 
signal of cell bodies and (B) dextran-Texas Red signal of vesicles; (C) 
merged fluorescent signals from (A) and (B) show co-localization (orange) 
of red vesicles within the green cell bodies. (D) Three-dimensional model 
rendered in 3D Slicer of network from (A-C). (E) FITC-phalloidin labeling 
of f-actin filaments and (F) dextran-Texas Red signal of vesicles; (G) 
merged fluorescent signals from (E) and (F), scale bar = 50µm. 
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Figure 3.3: Matrix-integrin-cytoskeletal axis study. Abbreviations: CytoB, cytochalasin 
B; Colch, colchicine; RGD, cyclic GRGDSP; RGE, cyclic GRGESP.            
(A) Average network length per microcarrier bead as measured by our 3D 
quantification method. (B-F) Z-stack projections representative of 
morphological outcomes reported in (A). *p < 0.05, versus 10P control. 
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Figure 3.4: MSC proliferation (A), endothelial marker expression (B and C), and protein 
secretion (D-G). (A) Results of the CellTiter 96 assay indicate slower MSC 
proliferation in PEGylated fibrin gels. (B and C) MSCs in PEGylated fibrin 
expressed significantly higher levels of endothelial markers vWF and VE-
cadherin, respectively. Images below graphs are representative of western 
blot chemiluminescent bands. (D) VEGF secretion and (E) MMP-2 
secretion normalized to cell number from (A). (F) and (G) are raw values for 
protein secretion reported in (D) and (E), respectively. (A, D-G) *p < 0.05, 
versus 10F control at same time point. (B,C) *p < 0.05, versus 10P. 
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Figure 3.5: Hypoxia inducible factor axis study. (A) Results of CellTiter 96 assay 
indicated no mitogenic response to VEGF or CoCl2 but a significant decline in MSC 
proliferation under 1% O2. (B) Increasing to 2% O2 reduced hypoxia-associated lag in 
MSC proliferation. (C) Average network lengths per microcarrier bead as measured by 
our 3D quantification method. Hypoxic stress increased VEGF secretion (D) and MMP-2 
production (E) of MSCs in PEGylated fibrin; values are normalized to cell numbers 
reported in (A). (F) and (G) are raw values for protein secretion reported in (D) and (E), 
respectively. (H-K) Z-stack projections representative of morphological outcomes in (C). 
*p < 0.05, versus 10P control at same time point. 
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Chapter 4: Vasculogenic mimicry as a new model for understanding 
endothelial-like behavior of MSCs 
OVERVIEW AND AIMS 
Chapter 4 relies on findings from Chapter 3 to pursue directed investigation of 
mechanisms responsible for MSC behavior in PEGylated fibrin. Though Chapters 3 and 4 
have been independently presented in this document, they will be merged into a single 
manuscript for future publication. The goals of Chapter 4 are outlined by Aim 3. 
 
Aim 3: Investigate the mechanisms responsible for endothelial-like MSC behavior in 
PEGylated fibrin gels. 
Rationale: MSCs in PEGylated fibrin exhibit a partial endothelial phenotype. The 
utility of endothelial-like cell behavior and why PEGylated fibrin elicits this cell 
response remains unknown. Understanding both questions is central to directing 
future applications of our cell-based ischemic therapy. 
A. Compare phenotypic and morphologic outcomes of MSCs to endothelial cells. 
B. From results of 2E, explore how implicated mechanisms modulate endothelial-
like behavior of MSCs. 
C. Validate findings of 3B with an in vivo model. 
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INTRODUCTION 
Stem cell-based therapies are a developing avenue for treating ischemia and 
chronic wounds.1-4 One strategy aims to locally deliver autologous cells within a 
biomaterial carrier, encouraging neovascularization and tissue recovery.5-7 Our group is 
working towards once such cell therapy: the delivery of bone marrow-derived 
mesenchymal stem cells (MSCs) within an in situ gelling PEGylated fibrin matrix.8 We 
have previously shown that PEGylated fibrin promotes spontaneous formation of MSC 
tubular networks without soluble factors.9 However, the vascular morphology is 
accompanied by an incomplete endothelial immunophenotype. As shown in Figure 4.1, 
MSCs in PEGylated fibrin consistently express von Willebrand factor (vWF) and 
vascular endothelial cadherin (VE-cadherin) but not platelet endothelial cell adhesion 
molecule (PECAM-1), which is highly specific to mature endothelial populations.10 The 
lack of complete differentiation towards an endothelial lineage has raised questions 
regarding the clinical utility of these MSC networks. Alternative cell-based approaches to 
neovascularization are developing endothelial-MSC co-culture systems, which instead 
use MSCs as a pericytic vascular support.11-13 The present lack of fully mature MSC-
derived endothelium motivated us to seek alternative explanations for this endothelial-
like behavior, aside from terminal transdifferentiation mechanisms. 
The majority of vascular tissue engineering strategies are inspired by normative 
developmental and postnatal biological processes. Diseased states, though, may offer new 
insights for achieving similar outcomes. A cancer-derived process for tissue perfusion, 
termed “vasculogenic mimicry” (VM), was first described in melanoma tumors in 1999.14 
As tumors reach critical levels of hypoxic stress, some develop an aggressive survival 
mechanism whereby dedifferentiated cancer cells adopt endothelial-like qualities and 
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become VM cells (see Figure 4.2 diagram).15,16 These VM cells form functional channels 
that anastomose with normal vasculature to divert blood flow into the tumor.17 Thus, VM-
capable tumors are able to alleviate hypoxic stress independent of classical endothelial 
cell (EC) mechanisms. In vascular biology, VM was the first evidence that perfusion of 
non-endothelialized networks is possible without clotting.18 
In regards to our research, VM cells notably share the same immunophenotype as 
MSCs in PEGylated fibrin, which first piqued our interest in this model. Specifically, 
both populations are vWF+/VE-cadherin+/PECAM1- and share mesenchymal-lineage 
characteristics.14,19 The functional abilities of VM cells in cancer, coupled with a semi-
endothelial immunophenotype, suggest that mature endothelialization may not be a 
requirement for therapeutically beneficial transient perfusion. This paradigm provides 
our field with a new perspective towards understanding how and why mesenchymal cell 
types may self-organize and perfuse tissues.  
Elucidating the driving mechanisms of MSC network development is necessary 
for understanding PEGylated fibrin’s therapeutic significance. Given the shared 
phenotypic characteristics of our MSCs and VM cells, we hypothesized that a 
mechanistic resemblance may also exist. Hypoxia is a catalyzing stressor that drives 
tumors towards VM; 20-22 thus, hypoxia should be investigated as similarly crucial for 
MSC tubulogenesis, specifically the hypoxia inducible factor (HIF) pathway. 
Furthermore, pilot studies from Chapter 3 established early indications that hypoxia 
modulates MSC behavior in our system as well. Under hypoxic conditions, MSC 
networks exhibited increased their production of VEGF and MMP-2.  
Additionally, three-dimensional (3D) substrates (by design) raise hypoxic stress 
compared to their two-dimensional (2D) analogues. As a recent study showed, cells in 3D 
substrates under normoxic conditions will still experience hypoxia while cells on 2D 
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substrates will not.23 Not all 3D substrates drive spontaneous MSC tubulogenesis, though. 
In a related study,24 we have observed that fibrin uniquely increases angiogenic signaling 
over other extracellular substrates, such as collagen or Matrigel. Cryo-SEM imaging has 
also demonstrated that fibrin PEGylation introduces amorphous packing regions within 
the typically fibrous gel, which slowed dye penetration and liquid filtration in diffusional 
studies (Chapter 3). These physical attributes suggest that PEGylated fibrin is more likely 
to cause a greater degree of hypoxia than unmodified fibrin gels alone. In light of VM, 
we now hypothesize that spontaneous MSC tubulogenesis is achieved through the 
synergy of two mechanisms: (1) biochemical signaling of angiogenic cues from fibrin and 
(2) increased hypoxia from PEGylation.  
With VM as a model, we aim to investigate (1) whether endothelial mimicry is 
unique to MSCs or also present in other mesenchymal populations and (2) if MSC 
network development is similar to VM in its dependence on HIF-mediated mechanisms. 
To our knowledge, this is the first time VM has been applied as an explanation for 
matrix-driven MSC network development. 
 
MATERIALS AND METHODS 
Materials 
Low-glucose Dulbecco’s modified Eagle’s medium (DMEM), phosphate buffered 
saline (PBS), fetal bovine serum (FBS), and Gluta-MAX™-I (100x) were purchased from 
Invitrogen (Carlsbad, CA). Penicillin-streptomycin and trypsin/ethylenediaminetetraa-
acetic acid were purchased from ATCC (Manassas, VA). Sigma-Solohill microcarrier 
beads (MCBs) coated in porcine collagen were obtained from Sigma-Aldrich (St. Louis, 
MO) as well as fibrinogen and thrombin from human plasma. Linear homo-difunctional 
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succinimidylglutarate polyethylene glycol (PEG-(SG)2, 3400 Da) was  purchased from 
NOF America (White Plains, NY). 
 
Cell culture of mesenchymal stem cells and normal dermal fibroblasts 
Human bone marrow-derived mesenchymal stem cells (MSCs) from Lonza 
(Basel, Switzerland) were cultured according to manufacturer specifications with growth 
medium in tissue culture-treated plastic flasks (Corning, Corning, NY) at 5000 cells/cm2. 
Normal human dermal fibroblasts (NHDFs; Promocell; Heidelberg, Germany) from adult 
skin were cultured with the same protocol. Growth medium consisted of DMEM 
supplemented with 10% FBS, 1% penicillin-streptomycin, and 2mM GlutaMAX™-I. 
MSCs were tested by the manufacturer for trilineage differentiation potential and for 
positive expression of CD105, CD166, CD29, and CD44; cells were negative for CD14, 
CD34, and CD45. Population purity was greater than 95%. NHDFs were tested for 
positive expression of the fibroblast specific antigen, CD90. Cultures were maintained at 
37°C and 5% CO2. 
 
Cell culture of microvascular endothelial cells 
Human dermal microvascular endothelial cells (HDMECs; Promocell; 
Heidelberg, Germany) from capillary vessels were cultured with endothelial growth 
medium in tissue culture-treated plastic flasks at 10000 cells/cm2. Endothelial growth 
medium consisted of DMEM supplemented with the Endothelial Growth Medium MV 2 
SupplementPack (Promocell), additional FBS up to 10%, and 1% penicillin-
streptomycin. HDMECs were tested for positive expression of vWF, CD31, and 
Podoplanin. Cultures were maintained at 37°C and 5% CO2. 
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Cell seeding of microcarrier-beads 
Cells were seeded on MCBs according to our previously described protocol, 
based on the modified bead-outgrowth assay developed by Nakatsu and Hughes.25,26 
Briefly, MCBs were suspended at 2 mg/mL in PBS, autoclaved, and stored at 4°C before 
use. Prior to seeding, MCBs were distributed as 4mg aliquots into FACS tubes and 
briefly centrifuged into a pellet to remove the PBS. Growth media was added for 1h to 
prime MCBs for cell seeding, which was then removed immediately before adding cells. 
Cells at passages 4-6 were trypsinized, centrifuged into a pellet, and re-suspended at a 
minimum concentration of 1.4×105 cells/mL growth media. MSCs and NHDFs were 
added to FACS tubes of MCBs for a final concentration of 7.0×104 cells/mg MCB and a 
total of 2mL growth media per FACS tube. HDMECs were seeded at a density 4× higher. 
Cells and MCBs were gently resuspended every 30min for the first 4h to evenly coat 
MCBs with cells. The cells and MCBs were then transferred to ultra-low adhesion 6-well 
plates for further coating overnight; the plate was gently agitated on an orbital shaker to 
minimize MCB aggregation. Seeded MCBs were strained through a 70µm mesh and 
rinsed with PBS to remove any unattached cells. Finally, MBCs were resuspended in 
300µL growth media/mg MCB. 
 
Three-dimensional gel culture in vitro 
Gel fabrication followed our previously described protocol for enzymatically 
crosslinked PEGylated fibrin and fibrin gels.8,9 Human fibrinogen was solubilized in PBS 
(without calcium or magnesium, pH 7.8) at 80 mg/mL. PEG-SG2 was similarly dissolved 
in PBS at 8 mg/mL. The PEG-SG2 concentrations correspond with a 10:1 molar ratio of 
reactive groups to each fibrinogen solution. Human thrombin was reconstituted in 
nanopure ddH2O to 100U/mL, which was further diluted to 25U/mL with 40mM CaCl2. 
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Gel components were passed through 0.22µm filters for sterility before use. Gels with 
1mL total volumes were fabricated in 12-well plates and those with 0.5mL total volumes 
in 24-well plates. Gel components were mixed in the following order using the same 
volumetric ratio: 1 fibrinogen: 1 PEG-SG2: 2 seeded MCBs: 4 thrombin. Gelation was 
finalized at 37°C for 15min before rinsing with PBS (with calcium and magnesium), 
followed by growth media rinses at 5min, 10min, 30min, and 1h to remove cytotoxic 
unreacted PEG-SG2. Gel culture was carried out to Day 7 with cell-specific growth media 
unless otherwise specified.  
 
Hypoxia cell culture 
For some experimental groups, MSCs in PEGylated fibrin were also cultured 
under 1% O2 using a hypoxia chamber (Stemcell Technologies; Tukwila, WA), 
generously loaned to us from Dr. Aaron Baker. The hypoxic gas mix was composed of 
5% CO2, 1% O2, and 94% N2 (Praxair; Danbury, CT). Cell cultures were environmentally 
isolated inside the hypoxia chamber with an open petri dish of water for humidity and 
placed in a 37°C oven. The chamber was purged with the hypoxic gas mixture for 5min 
and then purged again 90min later to evacuate any residual oxygen content from the 
culture media. Thereafter, the chamber was purged every 48h to maintain hypoxic 
cultures unless opened for assay endpoints. 
 
Fluorescent cell staining 
On day 7 of gel culture, samples were rinsed six times with PBS (with calcium 
and magnesium) for 15min each. Calcein AM (Invitrogen; Carlsbad, CA), a live-cell 
cytoplasm stain, was added at 10µM for 1h. Samples were rinsed four times with PBS 
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every 5min and then fixed with 4% neutral-buffered formalin for 30min. Finally, gels 
were briefly rinsed with 3 volumes of PBS to remove residual fixative and stored at 4°C 
overnight for imaging the next day. 
 
Two-photon microscopy 
Fluorescent z-stacks were collected of cell outgrowth from individual 
microcarrier beads with an Ultima Multiphoton Microscopy System (Prairie 
Technologies; Middleton, WI).  Two-photon excitation was achieved with a tunable 
Ti:sapphire laser (Spectra-Physics Mai Tai HP; Newport; Irvine, CA) set to 720nm under 
a 10x water-immersion objective. Z-slice thicknesses were adjusted to maintain isometric 
voxel dimensions. A thickness of 500-700µm was imaged along the z-axis for each 
image stack. 
 
Three-dimensional morphological quantification 
Image processing and three-dimensional morphological quantification followed 
our recently described method.9 As before, z-stacks were preprocessed in ImageJ 
(Release 1.2.4; ImageJ Plugin Project) and exported as Visualization Toolkit (.vtk) files 
and loaded into 3D Slicer (Release 3.6, 64-bit Linux), an open-source program for 
MRI/CT analysis. The Vascular Modeling Toolkit in 3D Slicer was used for image 
segmentation and 3D model generation. Centerline tracings of 3D models were exported 
as large data clouds of x,y,z coordinates with corresponding radii; the measured radius 
represented the model’s maximum cross-sectional diameter at each coordinate point. The 
data cloud was processed in MATLAB (Release 2008a for Macintosh) to calculate the 
average 3D network length per MCB. 
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Cellular protein detection with western blot 
Cells in gel matrices were lysed with RIPA buffer (Santa Cruz Biotechnology; 
Dallas, TX) and homogenized for 30s with a soft tissue grinder (OMNI International; 
Kennesaw, GA). Cell-gel lysates were passed through a 21-gauge needle 20× for further 
homogenization and solid gel remnants were removed through sample centrifugation at 
14000×g for 10min at 4°C. The supernatants were denatured in a reducing buffer of 
Laemmli sample buffer with 5% β-mercaptoethanol at 95°C for 5min. Denatured samples 
were separated with 10% mini-Protean® TGX™ precast gels (Biorad; Hercules, CA) at 
20µg protein per gel lane and blotted onto PVDF membranes. Membranes were blocked 
for 1h at room temperature with 5% (w/v) nonfat milk in TBST and then incubated 
overnight with a primary antibody at 4°C. Membranes were then rinsed with TBST 3× 
for 5min each and incubated with an HRP-conjugated secondary antibody for 1h at room 
temperature. After a second set of TBST rinses, 3mL of SuperSignal West Dura 
Chemiluminescent Substrate (Pierce Thermo Fisher Scientific; Rockford, IL) was added 
per membrane for 5min prior to image capture with a FluorChem CCD system 
(ProteinSimple; Santa Clara, CA). Chemiluminescent signal was quantified with 
AlphaView software for statistical analysis. For a list of antibodies and their dilutions, 
refer to Table 4.1. 
 
HIF-1α protein detection with ELISA 
Due to the small quantity of HIF produced in cells (compared to total sample 
protein of cells + degraded matrix) western blot analysis was insufficient for detecting 
this protein. Interference of the gel's protein matrix also prevented fractionation of the 
sample to enrich for nuclear content, where stabilized HIF-1a is located. A DuoSet 
ELISA (R&D Systems; Minneapolis, MN) was procured instead for detecting HIF-1a 
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using a larger sample volume. Since HIF-1α degrades rapidly upon exposure to normal 
oxygen levels, the method of obtaining protein supernatants was modified to minimize 
this risk. Briefly, all reagents were prepared and chilled before removing hypoxic cultures 
from the chamber environment. Once the chamber was opened, samples were 
immediately placed on ice and culture media quickly aspirated. As each sample was 
aspirated, RIPA buffer was added in succession. Samples (on ice) were placed on a side-
to-side rocker for 15min and then transferred to centrifuge tubes for centrifugation at 
14000×g for 10min at 4°C. Supernatants were directly used for ELISA according to the 
manufacturer’s instruction. Optical density was measured at 490nm. These OD values 
were normalized to DNA content, measured by nanodrop at 230nm. 
 
Chorioallantoic membrane assay 
Common quail embryos (Coturnix coturnix) were cultivated ex ovo in a modified 
version of the chorioallantoic membrane (CAM) assay.27-29 A cell culture incubator was 
modified to accommodate embryo growth. Briefly, the temperature was raised to 37.8°C 
and CO2 lowered to 0%. Instead of adding Fungizone to the humidity pan, autoclaved 
water with 1mM cupric sulfate (antibacterial) was used to minimize harmful vapors. A 
small fan was attached to the side port of the incubator to increase air circulation, 
improving embryo survival. One hundred quail eggs (Northwest Gamebirds; Kennewick, 
WA) were incubated until E2.5 before shell removal. Specialized egg-topping scissors 
were used to carefully remove eggshells and embryos were transferred to 60mm Petri 
dishes. Four open 60mm Petri dishes (each containing one embryo) were placed within 
150mm Petri dishes. Autoclaved water (with 1mM cupric sulfate) was added to the 
bottom of the 150mm Petri dishes to provide secondary humidification. During this time, 
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MSCs were pre-stained with DiI and encapsulated in 10mg/mL PEGylated fibrin gels at a 
concentration of 5×105 cells per mL ex vivo; microcarrier beads were not used for this 
study. On E8 (also, MSC culture Day 4), gels were sliced into six pieces. Two small 
pieces of gel were carefully laid on the peripheral CAM vasculature, avoiding direct 
coverage of major vessels. Onplants were covered with 100µL of media to maintain cell 
viability. On E11, quail embryos were sedated with isofluorene and intracardially 
injected with 2MDa FITC-dextran dye.30 The dye was allowed to circulate for 2min 
before terminating embryos by decapitation and removing the embryos from the CAM. 
CAMs were immediately fixed with 4% neutral buffered formalin overnight at 4°C.  
Fixed CAMs were rinsed with PBS, dissected further to remove any opaque yolk 
fragments, and oriented for imaging. Images were collected under wide-field 
fluorescence and phase-contrast. While the University of Texas at Austin IACUC does 
not require a protocol for avian embryos, American Veterinary Medicine Association 
guidelines for embryos beyond 50% gestational development were followed.31  
 
Statistical analysis 
A one- or two-way analysis of variance was used to determine significance 
between experimental groups. Where significance was found, post-hoc tests were 
performed to further determine specific relationships of statistical significance. Tukey’s 
correction for multiple comparisons was applied where appropriate. P-values less than 
0.05 were considered statistically significant. All statistical tests were completed in Prism 
(Version 6.0 for Mac OS X; GraphPad, La Jolla, CA). 
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RESULTS AND DISCUSSION 
MSC networks have more fibroblastic than endothelial character 
Our initial assumption was that MSC vascular morphogenesis behaviorally 
resembled normal endothelial cells during capillary development.32 Hence, we designed 
an experiment to validate this assumption of endothelial-type MSC behavior. In this 
experiment, MSC network morphology and phenotype were compared to mature 
microvascular endothelial cells and dermal fibroblasts. Human dermal microvascular 
endothelial cells (HDMECs) served as a positive control for capillary morphogenesis and 
represented the target MSC lineage. Similarly, undifferentiated MSCs and fibroblasts are 
well known to express overlapping surface markers and posses a characteristic spindle-
like morphology.33 Thus, normal human dermal fibroblasts (NHDFs) served as an 
appropriate negative control and represented the initial behavior of undifferentiated 
MSCs. 
Differences in matrix tunneling were immediately evident between HDMECs 
versus MSCs and NHDFs. In pilot studies, HDMECs were unable to sprout in PEGylated 
fibrin (without added VEGF stimulus) and were therefore cultured in pure fibrin gels at 
the same concentration as the PEGylated fibrin gels for MSCs and NHDFs. Even so, 
HDMEC networks were limited and unstable (Figure 4.3A), requiring morphological 
analysis after Day 4 (for all samples). Difficulty in achieving network formation from 
endothelial cells is well-known; mature endothelial cells have limited proteolytic 
abilities, requiring co-culture with fibroblasts or MSCs to rescue and sustain tubule 
assembly.34-37 MSCs and NHDFs both formed typical networks without regard for matrix 
density or PEGylation, as shown in Figure 4.3B and 4.3C, respectively. Quantification of 
these network morphologies reflected general observations. HDMEC networks were 
significantly shorter and more discontinuous than MSC and NHDF networks (Figure 
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4.3D). Furthermore, MSCs and NHDFs had networks of statistically similar lengths, 
indicating that MSC network coalescence more closely resembled fibroblastic than 
endothelial assembly. Morphological differences between MSCs and endothelial cells 
also carried through to their phenotypic character. While all three-cell populations 
expressed vWF (Figure 4.3E,G) and VE-cadherin (Figure 4.3F,G), HDEMCs expressed 
significantly higher levels than MSCs and NHDFs. MSCs and NHDFs were again 
statistically similar to each other. 
The results of this experiment were a pivotal turning point in our research path. 
MSC network morphology and phenotype strongly resembled fibroblastic more than 
endothelial behavior. The ability of MSCs to robustly migrate through dense PEGylated 
fibrin matrices indicated a clear departure from endothelial cell mechanisms, which allow 
for limited independent migration. Additionally, the inability of MSCs match endothelial 
cell expression of phenotypic markers highlighted their lack of complete differentiation 
towards an endothelial cell type. Endothelial-like behavior of NHDFs was also a 
remarkable result. Only one previous study clearly showed that NHDFs are capable of 
endothelial marker expression when cultured in monolayer with angiogenic growth 
factor-supplemented medium.38 In retrospect, the shared mesenchymal lineage of MSCs 
and NHDFs types suggests a behavioral overlap should (and does) exist, and fibroblasts 
are similarly known for having a mutable phenotype.39 Together, these findings suggest 
that endothelial-based literature is unlikely to shed light on mechanisms of MSC network 
development since this cell population departs from described endothelial behaviors. 
We sought an alternative (non-endothelial) literature base that would provide a 
more appropriate context and accurate explanation as to why (1) MSCs form tubular 
networks and (2) express endothelial markers suggestive of functional microvasculature 
but (3) lack a complete, mature endothelial phenotype. Functionally, vWF is secreted by 
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endothelial cells (and megakaryocytes) to carry clotting factor VIII in the circulation and 
is membrane-bound on activated endothelium to facilitate platelet adhesion;40,41 VE-
cadherin enables the formation of homotypic cell-cell junctions, which are necessary for 
regulating vascular permeability and promoting non-leaky transport.42 Non-endothelial 
presentation of VE-cadherin has been noted in literature but reports were limited to cells 
of the central nervous system, specifically astrocytoma cells and glioma.43 Generally, cell 
junctions mediated by cadherins (and combinations of cadherin accessory proteins) are 
regarded as cell-specific, and “cadherin switching” is associated with malignant 
phenotype cells transitions. Therefore, the presence of both vWF and VE-cadherin 
supports the conclusion that MSCs are pursuing vascular-type architecture with 
perfusional functionality. 
Vasculogenic mimicry (VM), a mechanism of tumor survival, offers a unique 
example of functional non-endothelialized networks.14 Tumor cells develop an 
endothelial-like phenotype, characterized by strong VE-cadherin expression along with a 
complement of other endothelial or stem markers, including vWF, Nodal, and CD133.44-46 
Importantly, these networks also have little-to-no PECAM-1 expression.14 Despite their 
immature endothelial phenotype, VM networks are capable of perfusing blood through 
microvascular channels without clotting.15 Thus, VM suggests that a mature endothelial 
phenotype may not be required to achieve functional microvasculature and endothelial-
like cell types are still therapeutically valuable.  
Mechanistically, vasculogenic mimicry is driven by a combination of integrin-
mediated matrix cues and the hypoxic stress of an increasingly dense tumor 
environment.46 Hypoxia leads to HIF-1α stabilization and nuclear translocation, where it 
promotes gene expression of VEGF, EphA2, Twist1, COX-2, and OPN.17,45 Twist1 in 
turn promotes expression of VE-cadherin, which is a hallmark protein of VM. Melanoma 
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cells that express negligible levels of VE-cadherin are unable to undergo vasculogenic 
mimicry.19,20 VE-cadherin is central in regulating phosphorylation of EphA2 and 
subsequent downstream activation of MMP-2 via MT1-MMP via phosphatidylinositol-3 
kinase (PI3K).47 Conversely, blocking EphA2 will lead to a decrease in VE-cadherin 
expression, VEGF production, and MMP-2 activity. Activation of MMP-2 leads to an 
increase in laminin γ2’ and γ2x deposition, and both laminin chains reciprocally 
encourage further cell migration and more laminin deposition.17 VM can be further 
potentiated by VEGF stimulation through autocrine VEGF production as well as 
“outside-in” integrin activation of focal adhesion kinase (FAK).48,49 Additionally, EphA2 
phosphorylation is associated with FAK-mediated Rac/Cdc42 activation of survival and 
proliferation cascades and “inside-out” signaling of integrin binding.49 The cumulative 
result of these self-perpetuating cascades is the significant upregulation of cell motility 
machinery and hypoxia responsive elements responsible for neovascularization, 
facilitating the invasive endothelial-like behavior of these tumor cells. 
With vasculogenic mimicry as a potential model for understanding endothelial-
like MSC behavior, we moved forward to investigate further similarities between VM 
and vascular morphogenesis in PEGylated fibrin. Here, fibrin provides the integrin-
adhesive matrix environment and the diffusion limitations of PEGylated fibrin, 
hypothetically, provide the necessary hypoxic stress. In particular, the following 
experiments were designed to differentiate between matrix-induced and hypoxia-induced 
endothelial-like behavior of MSCs and to what extent (if any) each contributes to 
vascular morphogenesis. 
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Fibrin bioactivity induces endothelial marker expression 
Our first experiment inspired by the VM model sought to uncover the impact of 
substrate cues on endothelial marker expression. To eliminate diffusion-associated 
hypoxia, MSCs were instead seeded as a 2D monolayer on top of three different thin gel 
substrates: fibrin, PEGylated fibrin, and collagen, all at 4mg/mL protein. Collagen served 
as a non-fibrin control to highlight any fibrin-specific outcomes. After seven days of 
culture, MSCs on PEGylated fibrin expressed significantly higher quantities of vWF 
(Figure 4.4A,C) and VE-cadherin (Figure 4.4B,C) proteins than MSCs on collagen. 
However, MSCs on fibrin expressed comparable levels of both proteins to MSCs on 
PEGylated fibrin. 
The results of this experiment indicate that fibrin is the bioactive component 
responsible for basal levels of endothelial marker expression. Furthermore, PEGylation 
does not alter the bioactivity of fibrin-mediated cuing. Some reports have suggested that 
PEG-fibrin conjugates have reduced fibrin bioactivity,50,51 but the fibrin in our gels 
appears unaffected. The results here also agree with another related study conducted by 
our group. We have previously observed that collagen increases adipose-derived MSC 
expression of smooth muscle actin, a marker of smooth muscle cell development.24 On 
fibrin-based substrates, MSC expression of smooth muscle actin was significantly lower. 
Prior and present results suggest a substrate-induced differentiation tradeoff may exist 
between endothelial-like and smooth muscle cell development. 
 
Hypoxic stress is key difference between fibrin and PEGylated fibrin outcomes in 
MSC vascular morphogenesis 
Our second experiment inspired by the VM model sought to elucidate the role of 
hypoxia in driving the endothelial-like behavior of MSCs in PEGylated fibrin. Here we 
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cultured MSCs in fibrin and PEGylated fibrin (in 3D) under normoxic conditions (Figure 
4.5A-C,G,H) to establish a normative trend. We then compared these results to a parallel 
set of gels cultured under hypoxia (1% O2) as a “gain of function” study (Figure 4.5D-F,I, 
J). Hypoxic stress under 1% O2 was confirmed by measuring HIF-1α protein levels of 
both normoxic and hypoxic samples after 24h of culture; HIF-1α protein was 
significantly higher in the hypoxic cultures of both fibrin and PEGylated fibrin MSCs 
relative to their respective normoxic controls (Figure 4.5K). 
Under normoxia, MSCs in PEGylated fibrin expressed significantly higher levels 
of vWF (Figure 4.5A,C) and VE-cadherin (Figure 4.5B,C) proteins. Given similar levels 
in 2D culture, this enhanced endothelial phenotype of MSCs in 3D PEGylated fibrin can 
be directly attributed to slowed diffusion profile caused by PEGylation, which is the only 
changed variable between the two groups. When fibrin and PEGylated fibrin gels are 
cultured under hypoxia, we find that the two gels once again induce similar levels of 
endothelial marker expression (Figure 4.5D-F). This equilibration between MSCs in 
fibrin and PEGylated fibrin suggests that fibrin-encapsulated MSCs may be “gaining 
function” through hypoxia-mediated upregulation of their endothelial program.  
As previously discussed in Chapter 3, the inability of hypoxia to further potentiate 
an endothelial phenotype in PEGylated fibrin-encapsulated MSCs may alternatively 
indicate that we have reached a stress plateau.52 Based on prior observations of slowed 
diffusion in PEGylated fibrin matrices, the oxygen available to MSCs in PEGylated fibrin 
will always be lower than that of MSCs in fibrin, all other factors being equal. Additional 
hypoxic stress, beyond that generated by the gel environment, may simply have 
diminishing benefits despite elevations in HIF-1α levels.53 So, at 1% O2, MSCs in fibrin 
may experience a desirable level of hypoxic stress that increases endothelial marker 
expression while MSCs in PEGylated fibrin experience slightly harsher hypoxic stress 
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that fails to elicit any further biological benefit. Thus, the equilibrated levels of 
endothelial markers may be a combinatorial effect of fibrin-encapsulated MSCs “gaining 
function” under hypoxia and PEGylated fibrin-encapsulated MSCs simply plateauing. In 
any case, hypoxic stress is clearly modulating the expression of an endothelial-like 
phenotype, which is sufficient evidence to implicate its importance within MSC vascular 
morphogenesis. 
In contrast to the phenotypic results, MSCs cultured under hypoxic environments 
were morphologically no different than their normoxic counterparts (Figure 4.5L). 
Networks formed in PEGylated fibrin were significantly longer than those in fibrin, 
regardless of oxygen levels. However, the general data trend suggests that MSC networks 
were slightly shorter under hypoxia, likely due to slower cell proliferation. Our previous 
characterization of MSC proliferation under hypoxic conditions indicated a dramatic 
decline under 1% O2 compared to normoxic controls (Chapter 3). Other studies have also 
demonstrated that MSCs are metabolically limited at early time points of hypoxic 
culture.54,55 Typically, hypoxia-stressed MSCs do not accelerate their growth (relative to 
normoxic controls) until after three weeks of culture so our results here are still reflective 
of normal behavior. Since vascular networks are multicellular structures, we can 
reasonably assume that hypoxia-limited cell proliferation would adversely impact 
network size. Statistically, the extent of impact here was minimal. 
 
Significance of VM-features in MSC vascular morphogenesis 
Despite improvements in vascular morphology and phenotype, MSCs in 
PEGylated fibrin are still not fully endothelial in nature. Endothelial and stem cell 
literature provided insufficient context for this hybrid cell state. Without context, we had 
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no foundation for validating its usefulness. In order to move forward with our work on 
stem cell-based ischemic therapies, we needed to understand the mechanisms underlying 
endothelial-like MSC behavior and uncover its functional meaning. 
The outcomes of this second study demonstrate that hypoxia is capable of 
catalyzing a stronger endothelial profile in MSCs, as it does for tumor cells in 
vasculogenic mimicry.20,21 Where the first study implicates fibrin-activated signaling as 
responsible for baseline endothelial expression, the second implicates a hypoxia-mediated 
response as the distinguishing cue between vascular morphogenesis in PEGylated fibrin 
versus fibrin. These findings draw stronger parallels between cancer cell and stem cell 
behavior. In many tumors, including VM-capable tumors, cells have previously de-
differentiated through an epithelial-to-mesenchymal transition.44,56 In VM, a portion of 
these cells gain new specificity towards an endothelial-like lineage while retaining some 
malignant and stem markers.44 With MSCs, we observe a similar phenomenon: MSCs 
develop characteristics of an endothelial-like lineage while retaining some mesenchymal 
features. In both cases, the presence of dual phenotypes raises interesting questions 
regarding hybrid cell states and cell functionality. Phenotypic overlap between VM cells 
and endothelial-like MSCs suggests the possibility of a shared function (i.e., development 
of perfusable networks). The additional ability of fibroblasts to match endothelial-like 
MSC behavior further suggests that VM-type behavior may be a more broadly shared 
trait of mesenchymal lineages. Disease models from cancer and non-normative biology, 
therefore, may be able to enlighten our understanding of less common cell states. 
Vasculogenic mimicry opens up new possibilities for achieving and validating tissue 
perfusion. Though VM-inspired approaches will likely produce imperfect networks, we 
can avoid the complexities of co-culture methods and soluble factor delivery. Transiently 
stable or leaky vasculature may be functional enough to sustain transplanted tissues in the 
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critical stages of host integration and rescue these tissues from necrosis. Until we can 
demonstrate functional perfusion of MSC networks, the evidence here should be regarded 
as circumstantial and more representative of a new perspective for vascular tissue 
engineering than a proven paradigm. 
 
FUTURE WORK 
Validating VM-type MSC vascular morphogenesis with an in vivo model 
Vasculogenic mimicry posits the utility of non-endothelial channels as perfusable 
networks for nutrient and oxygen transport. We have piloted the chorioallantoic 
membrane (CAM) assay as an in vivo model for demonstrating the utility of MSC-
derived vascular networks. The CAM assay is typically used for evaluating the 
angiogenic or anti-angiogenic characteristics of proteins, materials, and small 
molecules.27,57,58 More recently it has been adapted for more complex analytical methods, 
including vascular permeability studies, tumor metastases, and even cell-laden 
onplants.30,59,60 Here, we combine the ex ovo cultivation of Coturnix coturnix (i.e., the 
common quail) embryos with techniques for vascular permeability and cell-laden onplant 
studies to show perfusion of MSC networks. Although our application of the CAM assay 
is unconventional, we reasoned the lack of a host-mounted immune response to the 
onplants would enable clear observation of MSC-vascular interactions without the 
inundation of macrophages and other infiltrates. Inflammatory responses can obfuscate 
the contributions of transplanted cells to the local environment, complicating endpoint 
analysis. 
For our CAM protocol, MSCs were pre-stained with DiI and encapsulated in 
PEGylated fibrin gels ex vivo and cultivated for four days before being transplanted onto 
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the CAM of E8 quail embryos (Figure 4.6A). Three days later, E11 quail embryos 
(Figure 4.6B) were perfused with 2MDa FITC-dextran and terminated. The FITC-dextran 
size of 2MDa was chosen to mimic the size of low-density lipoprotein (LDL), a 
lipoprotein normally carried and taken up by healthy endothelium.30 CAM onplants were 
imaged with the intent of detecting FITC-dextran localization within DiI-stained MSC 
tubules. Figure 4.6C illustrates the fluorescent labeling schema of our in vivo model. 
We observed successful perfusion of FITC-dextran within the CAM vasculature, 
but no co-localization of FITC-dextran within DiI-MSCs was found. Instead, MSCs were 
clearly localized within the gel and CAM vasculature was clearly localized to the gel 
periphery (Figure 4.6D-I), suggesting a boundary layer issue between the inner and outer 
gel environments. The experimental variables that could have contributed to this outcome 
were too many to isolate individually. The boundary could have been caused by an 
unfavorable biomechanical gradient from the CAM to the onplant, discouraging vascular 
ingrowth; mature endothelial cells notably favor a softer matrix.61-63 MSCs, however, are 
typically more flexible in their migratory response to matrix densities. Their 
unwillingness to migrate from the gel suggests, instead, that the boundary layer is bi-
directional in inhibiting cell motility. This type of boundary issue is more likely to arise 
from the ex vivo formation of the gel onplants. A study on subcutaneous UV-crosslinking 
of PEG-dimethacrylate showed that ex vivo gelation incurred a significant gap between 
the gel and the surrounding tissue where as in situ gelation provided uniform gel-tissue 
integration.64 Hence, we recommend that future iterations of this in vivo model use in situ 
gelation to minimize the potential for boundary-layer issues.  
In situ gelation, though, introduces a new difficulty to overcome. MSC networks 
take approximately 7 days to form clear network structures and the CAM window for 
onplant integration is limited to 3-5 days due to the rapid fetal development of quails.65 
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This window is too short to allow for an ideal of study of MSC network behavior. A 
better model would 1) enable us to create in situ gels, 2) have 1-2 weeks of gel 
incubation, and 3) exert a minimal inflammatory response so we can isolate MSC-
vascular interactions. We propose an immunodeficient mouse model as a better candidate 
for in vivo examination of MSC vascular morphogenesis and its subsequent utility. 
Specifically, NOD/LtSzJ JAX mice (jaxmice.jax.org), which have a severely 
compromised innate immunity, advantageously support engraftment of human cells. 
 
CONCLUSIONS 
Our previous work focused on characterizing differences in biomaterial properties 
and MSC behaviors between fibrin and PEGylated fibrin matrices. Importantly, we found 
that PEGylated fibrin strongly drives vascular morphogenesis of encapsulated MSC 
populations, promoting the production of paracrine factors, matrix remodeling enzymes, 
tubular networks, and endothelial markers. However, the MSCs do not fully 
transdifferentiate towards an endothelial lineage and appear to depart from normative 
endothelial vascular assembly. A key experiment described here clearly demonstrated 
that MSC behavior is more characteristic of their originating fibroblastic character than 
the targeted endothelial lineage. The hybrid endothelial-mesenchymal features of MSCs 
(and fibroblasts) warranted the exploration of an alternative avenue for explaining the 
presence of such a cell type.  
The core work here encompasses a series of experiments predicated on 
vasculogenic mimicry as a new model for validating endothelial-like outcomes of MSCs. 
Vasculogenic mimicry provides a foundation for validating the development of hybrid, 
endothelial-like cell behavior. These experiments aim to clarify cellular mechanisms that 
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underlie our prior observations of MSC tubulogenesis in PEGylated fibrin and open up a 
new paradigm for understanding the therapeutic value of stem cell behavior. 
Despite hypoxic stress being a well-known cellular motivator in ischemic 
revascularization—and hypoxic preconditioning being a well-documented form of 
increasing transplanted cell survival—hypoxic stress as a biomaterial cue appears to be 
vastly overlooked and underestimated. Based on the results of this 3D study, hypoxia is 
clearly relevant in catalyzing endothelial-like MSC behavior. While fibrin matrices are 
capable of inducing basal levels of endothelial markers, the added hypoxic stress from 
PEGylated fibrin synergistically improves these cellular outcomes. Not only can vascular 
tissue engineering strategies target VM-type mechanisms of neovascularization, they can 
also incorporate hypoxia as an auxiliary biomaterial cue. 
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Antibody target 1°/2° Species Dilution Manufacturer 
CD31 (clone P2B1) primary mouse 1:100 Abcam (ab24590) 
von Willebrand factor primary rabbit 1:1000 Abcam (ab6994) 
VE-cadherin primary rabbit 1:700 Abcam (ab33168) 
β-actin primary rabbit 1:1000 Abcam (ab75186) 
Mouse IgG secondary rabbit 1:5000 Abcam (ab6728) 
Rabbit IgG secondary goat 1:5000 Santa Cruz Bio (sc-2004) 
Table 4.1: List of polyclonal primary and secondary antibodies used for western blot 
detection of cellular proteins. Antibodies were diluted in blocking buffer 
(5% nonfat milk in TBST). 
 
 
 
 
 
Figure 4.1: Summary of previously described endothelial-like behavior of MSCs in 
PEGylated fibrin with the addition of CD31- data. (A) Spontaneous MSC 
outgrowth from a microcarrier bead, Day 7; scale bar = 150µm. (B) 
Chemiluminescent bands detected via western blot analysis of cellular 
proteins; protocol used antibodies listed in Table 1. 
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Figure 4.2: Diagram of tubular vasculogenic mimicry, as first described by Maniotis et al 
in 1999. As the cell density of a tumor rapidly increases, the intratumoral 
environment becomes increasingly hypoxic. In response to the hypoxia, a 
subpopulation of de-differentiated tumor cells adopts an endothelial-like 
phenotype and begins forming tumor-lined tubular spaces. These non-
endothelialized tubes inosculate with normal endothelialized vasculature to 
divert blood flow into the tumor’s microenvironment. Tumors capable of 
this aggressive survival mechanism are associated with significantly poorer 
patient prognoses. 
 107 
 
 
 
Figure 4.3: Mapping the degree of endothelial-like MSC behavior. (A-C) Phase contrast 
images of cell outgrowth from the microcarrier bead (center; approximately 
150µm diameter). Specifically, (A) Human dermal microvascular 
endothelial cells (HDMECs) in a pure fibrin gel; (B) Bone marrow-derived 
human MSCs in PEGylated fibrin; (C) normal human dermal fibroblasts 
(NHDFs) in PEGylated fibrin. (D) Three-dimensional quantification of 
network outgrowth represented by (A-C). (E and F) Chemiluminescent 
signal of vWF and VE-cadherin protein, respectively, normalized to sample-
appropriate B-actin signal. (G) Chemiluminescent bands detected via 
western blot, as quantified in (E and F).    *p < 0.05, versus HDMEC. 
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Figure 4.4: Comparison of substrate-induced endothelial marker expression in 2D gel 
culture of MSCs. MSCs were seeded on top of thin gel substrates and 
cultured for 7 days under normoxic conditions. (A and B) 
Chemiluminescent signal of vWF and VE-cadherin protein, respectively, 
normalized to sample-appropriate B-actin signal. (C) Chemiluminescent 
bands detected via western blot, as quantified in (A and B). *p < 0.5, versus 
PEGylated fibrin. 
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Figure 4.5: Comparison of normoxia- and hypoxia-induced endothelial marker expression 
in 3D gel culture of MSCs. MSCs were seeded on microcarrier beads and 
encapsulated within gels, as previously described. Under normoxic 
conditions, (A and B) Chemiluminescent signal of vWF and VE-cadherin 
protein, respectively, normalized to sample-appropriate B-actin signal. (C) 
Chemiluminescent bands detected via western blot, as quantified in (A and 
B). Under 1% O2 hypoxic conditions, (D and E) Chemiluminescent signal of 
vWF and VE-cadherin protein, respectively, normalized to sample-
appropriate B-actin signal. (F) Chemiluminescent bands detected via 
western blot, as quantified in (D and E). Fluorescent z-projections of MSC 
outgrowth in (G) fibrin and (H) PEGylated fibrin under normoxia; (I) fibrin 
and (J) PEGylated fibrin under 1% O2 hypoxia. (K) HIF-1α protein 
normalized to sample DNA content. (L) Three-dimensional quantification of 
network outgrowth represented by (G-J). *p < 0.05, versus PEGylated fibrin 
in (A-E, L), versus normoxic control in (K). 
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Figure 4.6: Chorioallantoic membrane assay with quail embryos. Photographs of (A) E8 
embryo just prior to onplant addition and (B) E11 just prior to assay 
termination. PEGylated fibrin CAM onplant in (B) is indicated by circled 
area. (C) Diagram of fluorescent dyes utilized in the CAM assay. MSCs 
were labeled with DiI prior to gel encapsulation (red); the CAM vessels 
were visualized with a FITC-dextran injection on E11 (green). (D-I) Phase-
contrast images with fluorescent overlays of the CAM assay endpoint. (D 
and F) Peripheral growth of CAM vessels along onplant. (E) Termination of 
a CAM vessel directly into the boundary of an onplant. (G) Visualization of 
MSCs forming tubular structures; fluorescence only. (H) MSCs formed a 
large linear structure within the onplant, indicated by white arrows. (I) 
Radial growth of CAM vessels towards onplant; fluorescence only.  
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Chapter 5: Conclusions and Recommendations for Future Work 
PROJECT HISTORY 
The overall goal of this project was to deconstruct the mechanisms responsible for 
MSC tubulogenesis in PEGylated fibrin. This novel material was originally developed by 
Dr. Laura Suggs and colleagues at the University of Minnesota. Our group at the 
University of Texas at Austin has continued developing PEGylated fibrin as a therapeutic 
matrix for stem cell delivery in ischemic and wound-healing applications. The original 
design aimed to promote neovascularization via de novo assembly of perfusable MSC 
networks within PEGylated fibrin. The multipotency of MSCs held the promise of 
achieving simultaneous differentiation towards endothelial, smooth muscle cells, and 
pericytes—three cell types that comprise normal endothelial vasculature. Successful 
development of such a therapy where we can achieve neovascularization (1) with a single 
transplanted cell population and (2) without the need for additional soluble factors is of 
tremendous clinical interest. The simplicity would avoid many barriers to clinical 
translation. However, we have experienced issues when translating in vitro results to in 
vivo models. MSCs do not from robust networks in vivo, which have been the hallmark 
success of our in vitro studies. The project here sought to understand mechanisms of in 
vitro network formation so we may revisionally improve PEGylated fibrin for future in 
vivo trials. 
 
SUMMARY OF PRESENT FINDINGS AND CONCLUSIONS 
The development of a morphological quantification method based on three-
dimensional data has been a valuable technique in statistical analyses of MSC network 
outcomes (Chapter 2). Morphological analysis, combined with biological assays (surface 
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markers, protein production, and proliferation) allowed us to fully characterize MSC 
behaviors in PEGylated fibrin (Chapter 3). We found that MSC network development 
was inconsistent with that of normal endothelial cells (Chapter 4). Instead, these networks 
are more representative of a hybrid MSC cell state, with fibroblastic motility and 
endothelial-like marker expression. A similar event occurs in aggressive tumors though 
vasculogenic mimicry, whereby a subpopulation of tumor cells express a partial 
endothelial phenotype and self-assemble into perfusable networks. Vasculogenic mimicry 
in tumors is catalyzed by a combination of matrix cues (e.g., laminin deposition) and 
hypoxic stress from high cell densities. MSC tubulogenesis appears to be motivated by 
similar cues in PEGylated fibrin.  
Fibrin initiates a basic endothelial-like program in MSCs, resulting in baseline 
expression of vWF and VE-cadherin and production of VEGF. PEGylating fibrin slows 
the rate of diffusion in these matrices, increasing the hypoxic stress experienced by 
encapsulated cells. The added hypoxic stress appears key in differentiating PEGylated 
fibrin from naked fibrin matrices: MSCs in PEGylated fibrin exhibit significantly higher 
levels of endothelial markers and more robustly form continuous networks than in fibrin. 
These networks also form lumenal spaces, indicative of developing vasculature, through 
cell-hollowing mechanisms. These studies collectively provide new context for the 
presence of endothelial-like MSCs and suggests that complete transdifferentiation 
towards an endothelial lineage may not be necessary for therapeutic tissue perfusion. 
We recognize that immature vascular networks may have limitations. In 
vasculogenic mimicry, the tumor channels are functional but leaky and potentially less 
stable. Endothelial-like MSC networks may suffer from similar issues. With these 
limitations, MSC networks could still be functional enough to realize therapeutic 
benefits. Ischemic tissues, chronic wounds, and grafts simply need an early source of 
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perfusion to maintain viability until the host is able to fully integrate and remodel the 
tissue. MSC networks, which assemble much more quickly than normal endothelium, 
may transiently provide the necessary sustenance while the host vasculature invades. 
Essentially, the PEGylated fibrin patch could provide a vascular “band aid” in the 
treatment of ischemic tissue. 
 
AVENUES OF FURTHER INVESTIGATION 
PEGylation and integrin masking 
PEGylated fibrin-mediated MSC tubulogenesis may also be morphology-driven. 
Studies have shown that changes in cell morphology correlate with lineage-specific 
differentiation. In optimizing PEGylation of fibrinogen, we observed a terminal level of 
PEGylation where thrombin could no longer enzymatically crosslink fibrinogen. We 
hypothesized that PEGylation masked thrombin cleavage sites along fibrinogen and 
inhibited crosslinking. If PEGylation is capable of masking cleavage sites, it may also be 
masking integrin-binding moieties. Masking (some) integrin-binding sites on fibrin 
would force cells to extent further before establishing the next cell-matrix adhesion. 
Matrix-forced cell extension may enhance the vascular differentiation mechanisms of 
MSCs given the extended tubular nature of vascular-related cells. A study that was 
conceptualized (but not yet executed) would elucidate if and to what degree PEGylation 
masks integrin-binding sites in fibrin. By titrating doses of cyclic GRGDSP in fibrin-
based matrices, we can determine the saturation point where the peptide outcompetes 
matrix moieties. If our hypothesis holds true, we would expect that lower doses of cyclic 
GRGDSP to inhibit MSC migration in PEGylated fibrin than fibrin matrices. This finding 
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would provide another variable in our engineering arsenal that we can fine-tune for 
optimizing MSC tubulogenesis. 
 
Increasing matrix density to improve network maturity 
As described in Chapter 4, MSC networks are more fibroblastic than endothelial. 
A part of this character includes narrower lumens and overall cell diameter, which was 
more qualitatively observed than quantitatively measured. Endothelial networks 
described in literature have a more substantial lumenal width. Additionally, MSCs are 
highly migratory and produce significantly higher quantities of matrix-degrading MMPs 
than activated endothelial cells. While MMPs are necessary to facilitate cell tunneling, 
too much matrix degradation can lead to network overextension. Robust network 
development requires a balance of network-promoting and network-limiting (or 
stabilizing) kinetics. Increased production of MMPs may overdrive network-promoting 
kinetics and lead to rapid network extension without allowing time for cells to establish 
supportive adhesions and undergo necessary apical-basal polarization. Therefore, the 
advantageous motility of MSCs may also a detriment to network maturity and stability. A 
possible method of addressing this issue would be to increase the density of the 
PEGylated fibrin matrix, slowing MSC tunneling. However, a dramatic difference 
between the stiffness of PEGylated fibrin and the surrounding tissue may shift wound-
healing dynamics. Endothelial cells preferentially migrate on softer substrates. If our 
implanted matrix is too dense and too stiff, we risk inhibiting ingrowth of host 
vasculature. Studies would need to optimize the density of PEGylated fibrin that slows 
MSC growth but still yields to invading vessels. 
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In vivo models of MSC-endothelial inosculation 
As discussed in Chapter 4, the CAM assay may not be an ideal candidate for 
evaluating the possibility of MSC-endothelial inosculation. Ex vivo-formed gels create a 
significant boundary layer to vascular invasion by the CAM and MSC exodus from the 
gel. In situ-formed gels, due to the short gestational period of quail embryos, cannot be 
incubated on the CAM long enough for MSCs to establish networks. A subcutaneous 
model in a severely immunocompromised rat would allow longer 1-2 week incubation 
periods to better evaluate MSC-endothelial inosculation. The lack of an innate immune 
system would minimize obfuscation of MSC-specific events; analyzing the role of MSCs 
in the wound environment is easily complicated by a tremendous influx of macrophages 
and other inflammatory cells. This approach would mimic the naïve immune system of 
the CAM assay in a more durable model. 
Despite the appeal of evaluating isolated MSC-endothelial interactions, recent 
studies in our lab have implicated MSC modulation of macrophages as an important 
contribution to wound healing. An animal model lacking innate immunity would fail to 
recapitulate this aspect of normative healing. Additionally, prior experiences with 
subcutaneous models have periodically suffered from implant encapsulation and 
generally poor vascular invasion. More direct contact with vascularized tissue, such as 
subfascial implants, may be desirable for encouraging MSC-host interaction. 
 
Other in vivo models of clinical significance 
Alternatively, a free fat flap rat model could provide clinically relevant validation 
of PEGylated fibrin-encapsulated MSCs. Free fat flaps are a common reconstructive 
surgery technique to restore volume and vasculature to damaged tissue. However, 
surgeons must isolate subdermal vessels with the flap to facilitate graft survival. If MSCs 
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can indeed be a vascular “band aid,” this model would allow us to demonstrate transient 
sustenance of grafted tissue (by MSCs) and demonstrate relevance in another clinical 
application. 
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